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1. Introduction 
1.1 Lipidomics 
The ‘omics’ revolution has stimulated the concept of molecular profiling in biological 
systems. Although having been an intensive area of research already in the 1960s, 
lipid research has recently gained prominence with the emergence of lipidomics (1). 
Lipidomics can be defined as the system-level analysis and characterization of lipids 
and their interaction partners (2;3). A lipidome is the comprehensive and quantitative 
description of a set of lipid species e.g. constituting a cell. Lipidomics can be viewed 
as a sub-discipline of metabolomics (Figure 1). Furthermore, lipidomics can be 
subdivided into membrane, organelle, metabolism and mediator lipidomics (4) which 
address either the comprehensive and quantitative description of membrane lipid 
constituents, or the structural characterization and quantification of low abundant 
bioactive lipid species, respectively. 
 
DNA RNA Protein Metabolites
Genomics Proteomics Metabolomics
Lipids Sugars Toxins
LIPIDOMICS
Lipid isolation
Lipid analysis Pathway analysis
Lipid-protein interactions Lipid signalling and regulation  
 
Figure 1: Lipidomics – system level scale analysis of lipids and their interaction partners 
Genes encode proteins that collectively together with environmental factors, lead to the metabolite 
inventory of a cell, tissue or body fluid. Novel approaches now allow for qualitative and quantitative 
measurements at each level on global scales (genomics, proteomics and metabolomics). Lipidomics is 
a subgroup within the field of metabolomics (3). 
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1.1.1 Lipidomic development and goals  
Over the past 30 years basic cell biology has been a major driver of lipid research not 
only with respect to cholesterol homeostasis. Elegant experiments in model 
organisms including yeasts, worms, flies and mice have provided deep insight into 
lipid metabolism in living organisms. Using modern genetic approaches in 
combination with functional assays, these studies addressed the roles of many lipid 
enzymes, including lipases, kinases, phosphatases and transferases. Common to 
these studies is their focus on mechanistic aspects which is necessary to understand 
the biology of lipids at the molecular level.  
The major goal in lipidomics is the identification of metabolic pathways which are 
activated or deactivated during development of an organism or when a cell is shifted 
from an established physiological condition to another physiological or pathological 
condition (metabolic learning). A better understanding of the regulation of underlying 
metabolic pathways is necessary to design novel strategies for intervention (3;5). 
Lipids in biomembranes and others which are circulating as signaling molecules in 
our blood reflect physiological states during a given point in time. Side-by-side 
analysis of lipid and protein levels (overlay of lipidomics with proteomics) will help us 
understand better the molecular significance of the temporal relationships of 
metabolite and enzyme/effector fluctuations, and the careful analysis of lipids is likely 
to yield more refined and defined biomarkers (3;6). 
 
1.1.2 Classification and role of lipids 
For the future studies ranging from an overview of the entire lipidome to precise 
quantitative determination of rare bioactive lipid species will be necessary to reveal 
distinct lipid changes. To comprehend the entity of the whole lipidome several groups  
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of the lipidome have to be studied (Figure 2) (7). The inherent chemical diversity 
present in biological samples is achieved through multiple discrete covalent 
assemblies of a lipid backbone which is typically glycerol with linear combinations of 
various aliphatic chains alone (cholesteryl esters or triacylglycerols) or in conjunction 
with a high variety of polar head groups like spingolipids or phospholipids (8). This 
biological diversity facilitates the specific tailoring of cellular responses to alterations 
in cellular nutrient status, metabolic history, and signaling events. 
 
Retinoids and flavonoids
Lipid classes 
and species 
of the 
lipidome
Sterols/oxysterols/steroid hormones/ 
plant sterols
Complex glycolipids, including 
sulphated molecules
Sphingolipids and glycosphingolipids
Eicosanoids and other derivatives of 
ω3/ω6 polyunsaturated FA
Fatty acids (FA) including rare species like 
branched chain FA, conjugated FA, trans-
FA, oxidized FA, epoxy-FA, hydroxy-FA
Glycerophospholipids and oxidized 
species, including ether-linked lipids
Triacylglycerols including ether-linked 
species  
 
Figure 2: Lipid groups of the lipidome 
 
 
Pertinent to this thesis work are the three main classes of membrane lipids: 
glycerophospholipids, sphingolipids and sterols. 
 
Glycerophospholipids are the major components of biological membranes (9) and 
have inherent biological activities by acting as second messengers themselves or as 
precursors for the generation of second messengers. The principal feature of 
glycerophospholipids is the presence of a polar head group attached to the end of 
the glycerol backbone via a phosphodiester bond (10). They are chiral molecules 
divided into subclasses according to different head groups (Table 1).  
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Table 1: Chemical structures of glycerophospholipids and lyso-glycerosphospholipids 
Name Short name Chemical structure 
Phosphatidylcholine PC 
 
Phosphatidylethanolamine PE 
 
PE based plasmalogens PE-pl 
 
Phosphatidylglycerol PG 
 
Phosphatidylinositol PI 
 
Phosphatidylserine PS 
 
Lysophosphatidylcholine LPC 
 
 
 
Various fatty acids (FA) are linked to the glycerol backbone at sn-1 and sn-2 
positions via either two acyl linkages or one acyl and one alkyl linkage (10). 
Glycerophospholipids with an ether linked fatty alcohol moiety at the sn-1 position are 
subdivided into plasmalogen species (11). In mammalians, ether linkages occur 
predominantly in phosphatidylcholine (PC) and phosphatidylethanolamine (PE). For 
this study only PE-based plasmalogens were measured. Lysophospholipids have 
Introduction 5
only one FA moiety attached to the glycerol phosphate backbone. Their role as 
intracellular signaling molecules beside the function of membrane phospholipid 
metabolites is increasingly appreciated (12). They regulate a wide variety of cellular 
activities including proliferation, wound healing, smooth muscle contraction and tumor 
cell invasiveness (13). The cellular glycerophospholipids are compartmentalized and 
different compartments possess markedly different glycerophospholipid species 
which undergo differential transfer and turnover (14). 
 
Sphingolipids which are found in many living organisms (from yeast, plants, to 
humans) and in virtually all cell types, comprise more than 300 species (15); and this 
does not include the structural heterogeneity of the ceramide backbone. Besides 
playing structural roles in cellular membranes, sphingolipid metabolites act as 
bioactive signaling molecules involved in the regulation of cell growth, differentiation, 
senescence, and apoptosis (16). Bioactive sphingolipids are induced by several 
agonists, and, in turn, they regulate several downstream targets that mediate their 
various effects on cell function (16). Sphingolipids have also been reported to form in 
a dynamic cluster with sterols membrane microdomains which function as hubs for 
effective signal transduction and protein sorting (17). The common structural features 
of all sphingolipids are sphingoid bases (also termed long chain bases) composed of 
a hydrophobic moiety and a hydrophilic head group. Sphingolipids can be divided 
into two groups. The first group is termed sphingophospholipids and the second one 
glycosphingolipids which comprise of lacto-, globo- and gangliosides (15). The 
relevant sphingolipids for this study are shown in Table 2. It should be noted that the 
cellular levels of the various bioactive sphingolipids exhibit great differences. 
Concentrations of ceramide (Cer), sphingosine (Sph), and sphingosine-1-phosphate 
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(S1P) differ approximately by an order of magnitude, with Cer presenting the highest 
and S1P the lowest level (16).  
 
Table 2: Chemical structures of common sphingolipids 
Name Short 
name 
Chemical structure 
Ceramide Cer 
 
Glycosylceramide GlcCer 
 
Lactosylceramide LacCer 
Sphingomyelin SM 
 
Dihydrosphingomyelin DihSM 
 
Sphinganine SPA 
 
Sphinganine-1-phosphate SPA1P 
 
Sphingosylphosphorylcholine SPC 
 
Sphingosine SPH 
 
Sphingosine-1-phosphate S1P 
 
 
 
Sterols like cholesterol and its derivates are the most widely studied lipids for 
decades (18). Sterols are an important component of membrane lipids and a 
determinant of membrane organization (18). Mammals have developed sophisticated 
mechanisms to keep cellular sterol levels precisely controlled by regulation of 
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synthesis, influx and efflux (19;20). This structurally complex lipid class is implicated 
in numerous physiological functions including digestive processes (bile acids), 
hormonal actions (steroid hormones), tissue development (21) and regulation of cell 
membrane permeability (22). The major sterol cholesterol is mainly found in its “free” 
form or esterified to FA acyls (cholesteryl esters) (Table 3). Further prominent 
members of sterol lipids are bile salts and secosteroids (Vitamins D2, D3 and 
derivatives) (23) which were not under focus for this study. 
 
Table 3: Chemical structures of common sterol lipids 
Name Short name Chemical structure 
Cholesteryl ester CE 
Free cholesterol FC 
 
 
The enormous structural diversity of chemically distinct molecular lipid species arises 
from various combinations of different FA and functional headgroups linked with 
backbone structures (24). A large number of studies indicated that the number of 
different FA species found in mammalian lipids is typically in the order of 30–60 (3). It 
was estimated that the number of possible molecular lipids in a given biological 
system is in the order of 200,000 (1). However, many of these theoretically possible 
species do not exist in nature or exist in very low abundance. In crude tissue extracts 
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approximately ~100 molecular species are observed experimentally in a given class 
of glycerophospholipids (3).  
Additionally, lipids undergo extensive enzymatic as well as non-enzymatic 
modifications, which change their properties and functions. General enzyme classes 
are indicated in Figure 3. Many of these enzymes are tightly linked to signaling and 
implicated in a wide variety of processes including membrane trafficking, cell 
activation and many others (25). 
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Figure 3: Enzymatic modifications of lipids 
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The crucial role of lipids in cell, tissue and organ physiology is evident by 
- their unique membrane organizing properties that provide cells with 
functionally distinct subcellular membrane compartments and organelles (e.g. 
plasma membrane, endoplasmatic reticulum, Golgi apparatus, secretory 
vesicles, etc.), 
- their functional role in cell signaling (e.g. ceramide and sphingosine-1-
phosphate in cellular events including growth arrest, differentiation, and 
apoptosis), 
- their essential role for energy production, metabolism and storage, 
- and their endocrine actions (e.g. steroid hormones) (26). 
The critical role of lipids in cell, tissue and organ physiology is already demonstrated 
by many human diseases involving the disruption of lipid metabolic enzymes and 
pathways. Examples of such diseases include diabetes, cancer, neurodegenerative 
disorders and infectious diseases (3;27). 
 
1.2 Enabling technologies for the emerging field of lipidomics 
So far, the explosion of information in the fields of genomics and proteomics has not 
been matched by a corresponding advancement of knowledge in the field of lipids. 
This was largely due to the complexity of lipids because nature is synthesizing an 
enormous number of chemically and structurally distinct lipid species. Another reason 
was the lack of powerful tools for lipid analysis. Novel analytical approaches now 
allow for systems level analysis of lipids and their interacting partners. Two core 
technologies have emerged as the workhorses for lipid analysis: nuclear magnetic 
resonance (NMR) spectroscopy and tandem mass spectrometry (MS/MS) (28). NMR 
spectroscopy, which is used almost exclusively for analyzing small biochemicals in 
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the blood, requires relatively little sample preparation and is non-destructive, allowing 
further analysis. However, the method tends to have low sensitivity and can detect 
only highly abundant analytes. Lipid analysis is traditionally performed by gas 
chromatography–mass spectrometry (GC–MS), however, the recent development of 
electrospray ionization (ESI) (29) and matrix-assisted laser desorption/ionization 
(MALDI) (30) has significantly expanded the range of lipids that can be analyzed by 
MS in unfractionated materials (shotgun lipidomics). The coupling of ESI-MS to liquid 
chromatography (LC) has greatly increased the number of lipid classes studied in a 
single experiment. The Nobel Prize for John B. Fenn in chemistry 2002 also 
emphasized the importance of mass spectrometry for developments in this area. 
An overview of the different technologies used in lipidomic research is presented in 
Table 4 and was already nicely reviewed by Wenk (3). Furthermore, instruments 
capable of performing MS/MS provide the detailed structural information necessary 
for characterization of novel lipids, not previously possible, and the selectivity 
required for the determination of individual lipid species (28). MS/MS allows to 
determine analyte masses with such high precision and accuracy that lipids can be 
identified unambiguously in complex mixtures, therefore applicable to a wide range of 
biological samples (31). The developments for detection of phospholipid species in 
different cell types by high sensitivity and high throughput methods have especially 
contributed a lot to novel findings in lipidomics (32-35). The area of mass 
spectrometric quantitative analysis continues to emerge as an important application 
for biology and medicine because new lipid molecules continue to be discovered and 
some have profound action on cellular biochemistry (36). Therefore it can be stated 
that the success of lipidomics is primarily a result of technological advances in MS. 
The advantage of lipid MS is that it combines high-throughput analysis with high 
Introduction 11
sensitivity and resolution together with the ability of automated sample and data 
handling (37).  
 
Table 4: Technologies for lipidomic research (3) 
Technology Studied lipids Advantages Disadvantages 
Mass spectrometry    
MALDI many lipids TLC combination 
possible, direct 
detection by m/z 
Matrix backgrounds, 
ionization suppression 
ESI many lipids LC combination 
possible, direct 
detection by m/z,    
high sensitivity and 
selectivity, high 
turnover 
Absolute quantification 
involves significant 
effort, ionization 
suppression 
NMR    
1H all lipids Non-destructive,   
direct measurement 
Low sensitivity, spectra 
dominated by very 
abundant lipids 
31P phospholipids Non-destructive,   
direct measurement, 
quantitative 
Low sensitivity 
Chromatography    
Gas chromatography non-polar compounds Detection by mass 
spectrometry, mainly 
used for FA 
Requires derivatization 
of polar lipids or 
volatile compounds 
High-performance 
liquid chromatography 
many lipids Quantitative, easy 
automation 
Detection by mass 
detector or refractive 
index 
Thin-layer 
chromatography 
many lipids Technically easy, 
minor instrumental 
investment  
Low sensitivity and 
resolution drawbacks 
Biochemistry    
Photoactivatable lipids few Identification of lipid-
binding proteins 
Limited number of 
probes, specificity 
Lipid antibodies very few Study of cell biology Antibody specificity  
Immobilized lipids in 
assays 
many lipids Identification of ligand-
lipid interactions 
Automating and 
immobilization 
technically difficult 
Soluble lipids in assays many lipids Quantitative binding 
studies, high turnover 
Optimization 
challenging, technically 
difficult 
 
 
However, the biggest challenge of lipidomics remains the elucidation of important 
pathobiological phenomena from the integration of the large amounts of new data 
becoming available. Computational and informatics approaches allow studying lipid 
molecular profiles in the context of known metabolic pathways and established 
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pathophysiological responses. Lately computational background is available for 
automated calculations, where each compound entry is linked to the available 
information on lipid pathways and contains the information that can be utilized for its 
automated identification from high-throughput based lipidomic techniques (38). 
The new analytical tool for lipid detection combined with molecular imaging and 
modern information technology are able to revolutionize the understanding of the 
complex interaction networks in a functioning cell and how lipids together with genes 
and proteins determine cellular functions in health and disease.  
 
1.3 Human blood cells 
The entire blood volume recirculates throughout the body every minute, delivering 
oxygen and nutrients to every cell and transporting products from and towards all 
different tissues (39). The two main blood compounds are plasma and blood cells 
whereof the latter represents approximately 45% of the blood volume (40). Blood 
cells form a heterogenous mixture which continuously responds and adapts to the 
smallest changes in physiology. Consequently, blood cell analysis are of prime 
interest for both medical and science applications, and hold a central role in the 
diagnosis of many physiologic and pathologic conditions, localized or systemic (40). 
 
1.3.1 Types of blood cells 
Each type of blood cells is quite distinct in appearance and biological function (Figure 
4) (41): 
- Granulocytes and monocytes are myeloid cells which can exit from the blood 
compartment and migrate into many tissues and organs. Both cell types play a 
key role in innate immunity, inflammation and phagocytosis. 
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- Lymphocytes mediate specific immunity against microorganisms and other 
sources of foreign macromolecules. A distinction is drawn between B cells and 
T cells. B lymphocytes confer humoral immunity through the production of 
specific, membrane bound and soluble antibodies (humoral immune 
response), while T lymphocytes direct a large variety of immune functions, 
including killing of cells that bear foreign molecules on their surface 
membranes (cellular immune response). 
- Platelets are anucleate, very small cells that contain molecules stored in 
specific granules that are required for haemostasis. These cells provide 
haemostasis through their ability to adhere, aggregate, and by offering a 
surface for coagulation reactions. 
- Red blood cells (RBC) are anucleate, bioconcave discoid cells filled with 
haemoglobin, the major oxygen-binding protein. RBC transport beside oxygen 
also the respiratory gas carbon dioxide. 
Lymphocytes
Monocytes
Circulating 
blood cells
Red blood cells
Granulocytes
Platelets
 
Figure 4: The five types of circulating human blood cells 
 
Despite these extreme structural and functional differences among the blood cells, all 
of them share progeny of a single type of cell, the hematopoetic stem cell.  
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1.3.2 Origin and lifetime of blood cells 
In the bone marrow the hematopoietic stem cells differentiate into myeloid or 
lymphoid precursor cells (42) (Figure 5). The granulocyte-monocyte progenitors and 
the megakaryocyte-erythrocyte progenitors derive from the common myeloid 
precursor cell (43). The common lymphoid precursor cell differentiates to 
lymphocytes, the megakaryocyte-erythrocyte progenitors to megakaryocytes and red 
blood cells and the granulocyte–monocyte progenitors to granulocytes and 
monocytes (44). Monocytes can further differentiate into dendritic cells or 
macrophages after recruitment into peripheral tissues (44). 
 
Figure 5: Origin and haematopoietic differentiation of myeloid antigen-presenting cells published by 
Imhof and Aurrand-Lions (44).  
Abbreviations: DC: dendritic cell, NK: natural killer  
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The turnover and the replenishment of the hematopoietic system continues 
throughout life in contrast to organ systems that form in early life and are not 
continually replaced (41). In general the blood cell production is an enormously 
complex process. It can be calculated that each day an adult human produces 2x1011 
erythrocytes, 1x1011 platelets and 1x1011 leukocytes based on the adult blood volume 
(five liters) and the circulatory half-life of each of the blood cell types (45). However, 
the numbers of the various blood cell types are normally kept in relatively constant 
ranges because the blood cells have finite lifespans and the system of production, 
differentiation and elimination is strongly controlled (Table 5). While granulocytes and 
platelets circulate only a few days, red blood cells can exist for several months and 
some lymphocytes even exist for years as memory cells (41;46).  
 
Table 5: Absolute and relative number of cell populations and subpopulations and their lifetime in 
normal blood (adapted from (40)) 
Cell type Average/µL Percent of leukocytes Lifetime 
Granulocytes 
- Neutrophils 
- Eosinophils 
- Basophils 
 
4000–8000 
50–300 
0–100 
 
40%–66% 
1%–3% 
0%–1% 
~12 hours (47) 
Lymphocytes 1000–4000 20%–40% weeks to years 
(48;49) 
Monocytes 200–800 4%–8% 8-70 hours (48) 
Platelets 200,000–500,000  7-10 days (47) 
Red blood cells  5,000,000  ~120 days (50) 
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1.3.3 Blood cell storage and transfusion 
Worldwide, over 75 million units of blood are estimated to be donated every year 
(51). The ability to collect and store blood ex vivo in its liquid state is restricted to 
transfusion medicine institutions and blood banks (52).  
The reasons for blood transfusions can be the following:  
- massive blood loss due to trauma (53) 
- replacement of blood loss during surgery (54) 
- treatment of severe anaemia or thrombocytopenia caused by a blood cell 
disease (55) 
- treatment of patients with hemophilia, sickle-cell disease or other hemorrhagic 
disorders (56) 
Modern medical practice commonly uses only components of the blood. For this 
reason aphereses are performed where the blood of a donor or a patient passes 
through an apparatus which separates one particular constituent and returns the 
remainder back to the circulation. The separation of blood components is based on 
centrifugation by weight, filtration by size or a combination of both (57). 
It can be differentiated between four categories of component collections obtained 
from healthy donors (58): 
- Plasmapheresis: collection of blood plasma 
- Leukapheresis: collection of white blood cells 
- Plateletpheresis: collection of platelets 
- Erythrocytapheresis: collection of red blood cells 
Pertinent for this thesis were only two types of aphereses. The first one was 
leukapheresis which was utilized to obtain the different blood cell types (monocytes, 
lymphocytes, granulocytes and platelets) for subsequent lipidomic characterization. 
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The second one was plateletpheresis which was used in this work for subsequent 
lipidomic studies of platelet aging during storage. 
The storage conditions for different apheresis products with focus on time spent 
between donation and transfusion, are displayed in Table 6. 
 
Table 6: Storage conditions of apheresis products (59) 
Apheresis category Storage time Storage temperature 
Erythrocytapheresis 28-49 days 4°C±2°C 
Plasmapheresis 36 months -30°C±3°C 
Leukapheresis 1 day 22°C±2°C 
Plateletpheresis 4 days under agitation  (60) 22°C±2°C 
 
 
The storage of blood components in preservative medium is associated with 
metabolic, biochemical and molecular changes collectively referred as storage lesion 
(52). The storage lesion can eventually result in irreversible damage and reduced 
post-transfusion survival (52). Traditionally the term storage lesion has been 
restricted to corpuscular damage, but it was shown that a number of bioreactive 
substances accumulate in the medium during storage (52;61). 
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2. Aim of the thesis 
The blood cell compartment can be regarded as a liquid organ and blood cells are 
easily accessible compared to solid organs and tissues. Therefore the study of the 
blood cell compartment is a major interest of medical research especially the study of 
lipids which provide additional information of cellular function beside genomic, 
transcriptomic and proteomic knowledge. To determine lipid species in blood cells 
with high sensitivity the recent developments in electrospray ionization tandem mass 
spectrometry (ESI-MS/MS) opened new analytical options. The major aim of this 
thesis was to analyze the detailed lipid pattern of human blood cells by MS and 
reveal their lipid-specific features in healthy donors and related blood products. 
Firstly the different circulating human blood cells (monocytes, lymphocytes, 
granulocytes, platelets and red blood cells) of healthy donors were isolated by 
leukapheresis followed by counterflow centrifugation elutriation. Lipid extraction was 
performed according to Bligh and Dyer and the different lipid classes and species 
analyzed by ESI-MS/MS. Striking differences between the individual blood cell lipids 
were elaborated. 
In a second extensive study the reasons for the specific lipid composition of a single 
blood cell type should be elucidated. The cells of interest were the platelets because 
they revealed an interesting cholesteryl ester profile observed in the analysis 
described above. Therefore 50 platelet apheresis concentrates were stored for five 
days at 22°C under agitation and the cells and the plasma were daily isolated by gel-
filtration. The aim of this work was to study the influence of storage on the lipid 
pattern of platelet apheresis products and the effect of the plasma lipid environment 
on the cells.  
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3. Materials and Methods 
3.1 Materials 
3.1.1 Technical equipment 
Apheresis machine Trima Accel system   CaridianBCT, Lakewood, CO, USA   
Autoclave Steam Sterilizer Varioklav   Thermo Scientific, Waltham, MA, USA 
Autosampler HTS and HTC PAL    CTC Analytics, Zwingen, Switzerland 
Biofuge 15R       Heraeus, Hanau, Germany 
Cell Separator Spectra      CardianBCT, Lakewood, CO, USA 
Chromatography HILIC silica column   Interchim, Montlucan, France 
Clinical Chemistry System ADVIA 1800  Siemens Healthcare Diagnostics GmbH, Bad 
Nauheim, Germany 
FACS Canto      Becton Dickinson, Heidelberg, Germany 
Hematology analyzer ADVIA 120  Siemens Healthcare Diagnostics GmbH, Bad 
Nauheim, Germany 
Horizontal Shaker GFL-3016     GFL, Großburgwedel, Germany 
Ice Machine Scotsman AF-100    Progen Scientifc, London, United Kingdom 
Incubator B 6120      Heraeus, Hanau, Germany 
Lumi Imager F1      Boehringer, Mannheim, Germany 
Mass Spectrometer Quattro Ultima Triple Quadropole  Micromass, Manchester, UK 
Mass Spectrometer API 4000 Q TRAP   Applied Biosystems, Darmstadt, Germany 
Megafuge 1.0 R      Heraeus, Hanau, Germany 
Microplate Reader Sunrise™     Tecan, Crailsheim, Germany 
Mini Protean-3 Electrophoresis Cell    BioRad, Munich, Germany 
MiniSpin Plus Centrifuge     Eppendorf, Hamburg, Germany 
Mini-Sub Cell GT Electrophoresis    BioRad, Munich, Germany 
Pipetting Robot Genesis RSP 150    Tecan, Maennedorf, Switzerland 
pH-Meter pH537      WTW, Weilheim, Germany 
Precision Balance Sartorius MD BA 200   Sartorius, Göttingen, Germany 
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Power Supply PAC 300     BioRad Laboratories, Munich, Germany 
Pumps (binary) Agilent 1100 and 1200   Agilent, Waldbronn, Germany 
Shaking Water Bath Julabo SW-20C    Julabo, Seelbach, Germany 
Ultrasonic Water Bath Bandelin Sonorex   Progen Scientific, London, UK 
Ultrasonic Disintegrator Soniprep 150 MSE   Beun de Ronde, Abcoude, The Netherlands 
Ultracentrifuge Optima Max XP     Beckman Coulter, Krefeld, Germany 
Ultracentrifuge Optima TLX     Beckman Coulter, Krefeld, Germany 
Vacuum Concentrators Christ RVC    Wolf Laboratories Limited, York, UK 
Vortex-Mixer REAX 2000     Heidolph, Kelheim, Germany 
Water Purification System Milli-Q   Millipore, Eschborn, Germany 
 
3.1.2 Consumables 
Cell culture flasks (Nunc)  Thermo Fisher Scientific, Langenselbold, 
Germany 
Columns PD-10      GE Healthcare, Freiburg, Germany 
Cups (0.5, 1.5, 2.0ml)      Eppendorf, Hamburg, Germany 
ECL Hyperfilm Amersham    GE Healthcare, Freiburg, Germany 
ELISA 96 MicroWell plates    Nunc, Langenselbold, Germany 
Falcon tubes (15, 50ml)     Sarstedt, Nümbrecht, Germany 
Filter tips (2, 10, 20, 200, 1000μl)    Eppendorf, Hamburg, Germany 
Latex gloves       Hartmann, Heidenheim, Germany 
PVDF membranes     Pall Filtron GmbH, Dreieich, Germany 
Sterile filter       PALL, USA 
X-Ray films Biomax      Kodak, Rochester, NY, USA 
 
3.1.3 Reagents 
Acetyl chloride (puriss. p.a.)    Sigma, Taufkirchen, Germany 
Adenosine diphosphate (ADP)     DiaAdin, DiaMed, Cressier, Switzerland 
Ammonium acetate (SigmaUltra)    Sigma, Taufkirchen, Germany 
Bovine serum albumin (BSA, lipid-free)    Sigma, Taufkirchen, Germany  
Material and Methods 21
Cholesterol and cholesteryl ester standards  Sigma, Taufkirchen, Germany 
[25,26,26,26,27,27,27-D7]-cholesterol   Cambridge Isotope Laboratories, Andover,  
       USA 
Chloroform (HPLC grade)    Merck, Darmstadt, Germany 
Complete mini protease inhibitor cocktail   Roche, Mannheim, Germany 
EDTA (di-sodium)      GE Healthcare, Freiburg, Germany 
Glucose      Merck, Darmstadt, Germany 
Hepes       Merck, Darmstadt, Germany 
Lipid standards      Avanti Polar Lipids, Alabaster, USA 
       Toronto Research, North York, Canada 
Methanol (HPLC grade)    Merck, Darmstadt, Germany 
NuPAGE® LDS 4x sample buffer   Invitrogen, Karlsruhe, Germany 
NuPAGE® MOPS SDS running buffer    Invitrogen, Karlsruhe, Germany 
Phosphate buffered saline (PBS) w/o Ca2+/Mg2+  Gibco BRL, Berlin, Germany 
Protein standard precision plus (all blue)  BioRad Laboratories, Munich, Germany 
Ready gels, 4-20%      Invitrogen, Karlsruhe, Germany 
Sepharose 2B      Sigma, Taufkirchen, Germany 
Sodium dodecylsulfate (SDS)    Roth, Karlsruhe, Germany 
Thrombin receptor-activating peptide 6 (TRAP-6)  Bachem, Weil, Germany 
All other chemicals and solvents were from Sigma, Taufkirchen, Germany 
 
3.1.4 Antibodies 
Western Blot: 
ApoA-I (rabbit, polyclonal)     Calbiochem, Darmstadt, Germany 
ApoA-IV (rabbit, polyclonal)    Gift of Prof. Dieplinger (Division of Genetic 
       Epidemiology University of Innsbruck, Austria) 
ApoC-I (clone 10F4) (mouse, monoclonal)  MP Biomedicals, Solon, USA 
ApoE (goat, polyclonal)     Calbiochem, Darmstadt, Germany 
CD36 (rabbit, polyclonal)    Acris Antibodies, Herford, Germany 
 
Material and Methods 22
Goat (rabbit, polyclonal)  Jackson Immuno Research (Hamburg, 
Germany) 
Mouse (goat, polyclonal)  Jackson Immuno Research (Hamburg, 
Germany) 
Rabbit (goat, polyclonal)  Jackson Immuno Research (Hamburg, 
Germany) 
Transferrin (rabbit, polyclonal)     Acris Antibodies, Herford, Germany 
 
Flow cytometry: 
FITC-anti-CD62P      Beckmann Coulter, Krefeld, Germany  
FITC-anti-CD63      Coulter-Immunotech, Marseilles, France 
PE-anti-CD41       Beckmann Coulter, Krefeld, Germany 
PE-anti-CD36 BD      Biosciences Pharmingen, Heidelberg,  
       Germany 
PerCP-anti-CD61      Becton Dickinson, Heidelberg, Germany 
 
3.1.5 Kits 
BCA assay kit       Uptima-Interchim, Montluçon, France 
ECL plus western blotting analysis system  GE Healthcare, Freiburg, Germany 
 
3.1.6 Analysis software 
FACSDiva software      Becton Dickinson, Heidelberg, Germany 
MassLynx software including the NeoLynx tool   Micromass, Manchester, UK 
Microplate reader software Magellan™    Tecan, Crailsheim, Germany 
SPSS 15.0 software for Windows    SPSS Inc., Chicago, USA  
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3.2 Methods 
3.2.1 Blood cell isolation 
3.2.1.1 Isolation of red blood cells (RBC) 
RBC were isolated according to Breitling-Utzmann et al. (62) with slight modifications. 
Briefly, 4ml venous blood was collected from healthy donors into sterile EDTA tubes 
and blood cells were pelleted by centrifugation at 2700 x g for 30min at 4°C. Plasma 
and buffy coat were removed. The packed red cells were washed three times with 
PBS by subsequent centrifugation (2700 x g for 4min at 4°C). Erythrocyte cell 
number and purity was analyzed by an ADVIA 120 cell counter (Siemens Healthcare 
Diagnostics GmbH, Bad Nauheim, Germany). In parallel a blood smear was 
performed as control to evaluate the shape of erythrocytes. Only erythrocyte samples 
without fragmentocytes were used for further examination. After washing with PBS, 
the cell pellets were stored at -80°C. 
3.2.1.2 Isolation of monocytes, lymphocytes, granulocytes and platelets from 
leukapheresis products 
Blood cells were collected by leukapheresis in a Spectra cell separator (CardianBCT, 
Lakewood, CO, USA), followed by subsequent counterflow centrifugation elutriation 
as described elsewhere (63). In brief, cells were elutriated in the order platelets, 
lymphocytes, monocytes and granulocytes. Aliquots of the different cell fractions 
were analyzed for cell purity with a BD FACSCanto (Becton Dickinson, Heidelberg, 
Germany) determining the cell size with linear forward scatter and granularity and cell 
shape with logarithmic sideward scatter format of the BD FACSDiva Software. The 
cell numbers were determined by an ADVIA 120 cell counter (Siemens Healthcare 
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Diagnostics GmbH, Bad Nauheim, Germany). After washing with PBS, the cell pellets 
were stored at -80°C. 
3.2.1.3 Aging and isolation of platelets and plasma from platelet apheresis 
products 
Platelet concentrates were obtained after platelet apheresis on an Amicus (Fenwal, 
Mont Saint Guibert, Belgium) or a Trima Accel system (CaridianBCT, Lakewood, CO, 
USA). Any additive solution except acid citrate dextrose solution A (ACDA) was 
added to the platelet concentrates. After collection platelet concentrates were stored 
for five days at 22°C under continuous horizontal agitation. The platelet concentrates 
were opened under sterile conditions and approximately 5ml of platelet rich plasma 
(PRP) was removed each day from day 0 (day of collection) until day five. After 
removal of PRP from platelet apheresis products they were sealed under sterile 
conditions and were kept for further 24h at 22°C under continuous shaking. Platelets 
were separated from plasma components using gel-filtration. The platelet 
concentrates were opened under sterile conditions and 2ml of PRP layered onto a 
column (column volume: 13.5ml) (GE Healthcare, Freiburg, Germany) filled with 
Sepharose 2B in calcium-free Tyrode-Hepes buffer (138mM NaCl, 3mM KCl, 12mM 
NaHCO3,  0.4mM NaH2PO4, 1mM MgCl2, 5mM glucose, 10mM Hepes, 10mM EDTA, 
0.5% (w/v) BSA), pH 7.4, sterile-filtrated. Dead volume of 2.5ml was discarded and 
fractions 3-5 (elution volume: 2.5-5.0ml) collected and pooled together (Figure 6). 
The cell number of the separated platelets was quantified by the ADVIA 120 
hematology analyzer (Siemens Healthcare Diagnostics GmbH, Bad Nauheim, 
Germany). Platelets were disrupted by sonication on ice (Soniprep 150, Beun de 
Ronde, Abcoude, The Netherlands). To obtain plasma, 2ml of PRP were centrifuged 
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sequentially twice at 1500 x g for 10min and the supernatant harvested. Platelets and 
plasma were stored at -80°C before lipid extraction.  
 
1 2 9 10 11 123 4 5 6 7 8
1 2 3 4 5 6
2 ml 
PRP
Platelet pool
 
Figure 6: Platelet separation by gel-filtration procedure 
Two millilitres of platelet rich plasma (PRP) was layered onto a column and the platelet fractions 3-5 
were collected and pooled for analysis while fraction 6 was discarded. The rising plasma content in the 
fractions was nicely visible by stronger yellowish colouring. 
 
3.2.2 Flow cytometry  
Platelet activation was examined by anti-CD62P, -CD63, -CD41, -CD36 and -CD61 
antibody expression analysis before and after gel-filtration isolation in a BD 
FACSCanto (Becton Dickinson, Heidelberg, Germany) flow cytometer equipped with 
BD FACSDiva Software as previously described (64). Briefly 10µl of platelet samples 
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(10x dilution) were incubated for 10min with 10µl of PBS acting as control, 30µM 
thrombin receptor-activating peptide 6 (TRAP-6) (Bachem, Weil, Germany) and 5µM 
adenosine diphosphate (ADP) (DiaAdin, DiaMed, Cressier, Switzerland), 
respectively. After activation 10µl of the appropriate platelet antibody was added and 
incubated for 5min before resuspension in PBS and subsequent flow cytometric 
analysis. For each measurement data from 5,000 platelets were acquired.  
 
3.2.3 Proteomics 
3.2.3.1 Protein determination 
Protein concentrations were measured according to Smith et al. (65) using BCA 
Assay of Uptima-Interchim (Montluçon, France) with bovine serum albumin as 
standard. The haemoglobin content of the RBC was quantified by the ADVIA 120 
system (Siemens Healthcare Diagnostics GmbH, Bad Nauheim, Germany). 
3.2.3.2 SDS-PAGE 
45µl of each fraction gained by gel-filtration separation were mixed with 15µl 
NuPAGE® LDS 4x sample buffer (Invitrogen, Karlsruhe, Germany) and incubated for 
10min at 70°C in the presence of 50 mM DTT. Samples were run on 4–12% Bis-Tris 
gels (Ready Gels, Invitrogen, Karlsruhe, Germany) with NuPAGE® MOPS SDS 
running buffer (Invitrogen, Karlsruhe, Germany) at 200V per gel. Proteins separated 
within the gels were subsequently transferred to a PVDF membrane. Incubation with 
antibodies against CD36, transferrin, ApoA-I, ApoA-IV, ApoC-I or ApoE was 
performed in 1% non-fat dry milk in PBS and 0.1% Tween-20. The immune 
complexes were detected with an ECL plus Western blot detection system (GE 
Healthcare, Freiburg, Germany).  
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3.2.4 Lipidomics 
3.2.4.1 Sample preparation for mass spectrometry analysis 
Cell pellets were dissolved in deionised water (Millipore, Eschborn, Germany) and 
disrupted by sonication on ice (Soniprep 150, Beun de Ronde, Abcoude, The 
Netherlands). For lipidomic comparison of blood cells an aliquot corresponding to 
100µg of cellular protein was used for mass spectrometric lipid analysis. For the later 
platelet senescence study 100µl of the pooled platelet fractions 3-5 were used to 
analyze the different sphingolipids. For glycerophospholipid and sterol measurements 
an aliquot of 300µl of the pooled platelet fractions 3-5 and 20µl of plasma was used. 
Lipid extraction was preformed according to the method of Bligh and Dyer (66) in the 
presence of non-naturally occurring lipid species as internal standards. The following 
lipid species were added as internal standards: PC 14:0/14:0, PC 22:0/22:0, PE 
14:0/14:0, PE 20:0/20:0 (di-phytanoyl), PS 14:0/14:0, PS 20:0/20:0 (di-phytanoyl), 
PG 14:0/14:0, PG 20:0/20:0 (di-phytanoyl), PI 16:0/16:0 or PI 17:0/17:0, LPC 13:0, 
LPC 19:0, Cer 14:0, Cer 17:0, D7-FC, CE 17:0 and CE 22:0. The chloroform phase 
was dried in a vacuum centrifuge and dissolved in 10mM ammonium acetate in 
methanol/chloroform (3:1 vol/vol). Free cholesterol (FC) was analyzed after selective 
derivatization using acetyl chloride (35).  
For the sphingolipids except SM and Cer a butanolic extraction procedure according 
to Baker et al. (67) was used with the following internal standards: [13C2D2]S1P, SPH 
C17:1, SPC C17:1, GluCer C12:0 and LacCer C12:0. The butanol phase was 
evaporated to dryness under reduced pressure and the dried sample dissolved in 
ethanol.  
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3.2.4.2 Lipid mass spectrometry 
Lipid species were quantified by electrospray ionization tandem mass spectrometry 
(ESI-MS/MS) using methods validated and described previously (35;37;68-71). In 
brief, samples for the glycerophospholipid and sterol analysis were analyzed by direct 
flow injection on a Quattro Ultima triple-quadrupole mass spectrometer (Micromass, 
Manchester, UK) by direct-flow injection analysis using a HTS PAL autosampler 
(CTC Analytics, Zwingen, Switzerland) and an Agilent 1100 binary pump (Waldbronn, 
Germany) with a solvent mixture of methanol containing 10 mM ammonium acetate 
and chloroform (3:1, v/v). A flow gradient was performed starting with a flow of 
55μl/min for 6s followed by 30μl/min for 1.0min and an increase to 250μl/min for 
another 12s.  
The sphingolipid analysis except for SM and Cer was performed by liquid 
chromatography tandem mass spectrometry (LC-MS/MS) with an API 400 Q-Trap 
mass spectrometer equipped with a Turbo V source ion spray used for detection 
(Applied Biosystems, Darmstadt, Germany). The HPLC equipment consisted of an 
Agilent 1200 binary pump (G1312B), a 1200 series isocratic pump (G1310A) and a 
degasser (G1379B) (Waldbronn, Germany) connected to an HTC Pal autosampler 
(CTC Analytics, Zwingen, Switzerland). Gradient chromatographic separation was 
performed on an Interchim hydrophilic-interaction chromatography silica column (50 x 
2.1 mm) (Montlucan, France) with a 2.2µm particle size and equipped with a 0.5µm 
pre-filter (Upchurch Scientific, Oak Harbor, WA, USA). For GlcCer, LacCer, SPH, 
SPA, S1P and SPC detection the Applied Biosystems TurboIonSpray source was 
operated in positive-ionization mode with an analysis time of 4.5 min per sample 
while S1P and SA1P were detected in negative-ionization mode with an analysis time 
of 2.2 min per sample. The mobile phase consisted of water containing 0.2% formic 
acid and 200mM ammonium formate for measurement in positive-ionization mode 
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and 90mM ammonium formate for measurement in negative-ionization mode (eluent 
A), respectively. Eluent B consisted of acetonitril containing 0.2% formic acid. The 
gradient elution for detection of GlcCer, LacCer, SPH, SPA, S1P, SA1P and SPC 
was performed with 100% B for 0.1 min, a step to 90% B until 0.11 min, a linear 
increase to 50% B until 2.5 min, 50% B until 3.5 min and reeqilibration from 3.5 to 4.5 
min with 100% B. In case of detection of S1P and SA1P a gradient elution was 
performed with 5% A for 0.7 min, a linear increase to 25% A until 1.5 min, 50% A until 
1.7 min, and reequilibration from 1.7-2.5 min with 5% A. The flow rate was set to 
800µl/min (71). All analytes were monitored in the multiple reaction monitoring 
(MRM). 
A precursor ion scan of m/z 184 specific for phosphocholine-containing lipids was 
used for phosphatidylcholine (PC), sphingomyelin (SM) (70) and 
lysophosphatidylcholine (LPC) (37). Neutral loss scans of m/z 141 and m/z 185 were 
used for phosphatidylethanolamine and phosphatidylserine (PS), respectively (68). 
PE based plasmalogens (PE-pl) were quantified according to the principles described 
by Zemski Berry et al. (72). In brief, fragment ions of m/z 364, 380 and 382 were 
used for PE p16:0, p18:1 and p18:0 species, respectively. Ammonium-adduct ions of 
phosphatidylglycerol (PG) and phoshatidylinositol (PI) were analyzed by neutral loss 
scans of m/z 189 and 277, respectively (73). FC and CE were quantified using a 
fragment ion of m/z 369 (35). Sphingosine (d18:1) based ceramides (Cer) were 
analyzed by product ion of m/z 264 similar to a previously described method (69). 
After identification of relevant lipid species, selected ion monitoring analysis was 
performed to increase precision of the analysis for the following lipid classes: PE, PE-
pl, PG, PI, PS, LPC, Cer, CE. In case of S1P and SA1P the product ion spectra 
showed only a single intense fragment of m/z 79 used for analysis. Fragment ions of 
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m/z 282, 284 and 184 were used for SPH, SPA and SPC, respectively. Precursor ion 
scans of m/z 264 could be attributed to the glycosphingolipids GlcCer and LacCer. 
Quantification was achieved by calibration lines generated by addition of naturally 
occurring lipid species to cell and plasma homogenates respectively. All lipid classes 
were quantified with internal standards belonging to the same lipid class, except SM 
(PC internal standard) and PE-based plasmalogens (PE internal standards). 
Calibration lines were generated by adding the following naturally occurring species 
PC 34:1, 36:2, 38:4, 40:0 and PC O 16:0/20:4; SM 16:0, 18:1, 18:0; LPC 16:0, 18:1, 
18:0; PE 34:1, 36:2, 38:4, 40:6 and PE p16:0/20:4; PS 34:1, 36:2, 38:4, 40:6; Cer 
16:0, 18:0, 20:0, 24:1, 24:0; FC, CE 16:0, 18:2, 18:1, 18:0, GlcCer 16:0, LacCer 16:0, 
24:0 and the naturally occurring sphingolipid classes S1P, SA1P, SPA and SPC. 
These calibration lines were also applied for not calibrated species, as follows: 
Concentrations of saturated, monounsaturated and polyunsaturated species were 
calculated using the closest related saturated, monounsaturated and polyunsaturated 
calibration line slope, respectively. For example PE 36:2 calibration was used for PE 
36:1, PE 36:3, PE 36:4; PE 38:4 calibration was used for PE 38:3 and PE 38:5 and 
so on. Ether-PC species were calibrated using PC O 16:0/20:4 and PE-based 
plasmalogens were quantified independent from the length of the ether-linked alkyl 
chain using PE p16:0/20:4.  
The quantitative values were related to the plasma volume, protein amount or cell 
number of the sample, respectively. Correction of isotopic overlap of lipid species as 
well as data analysis was performed by self-programmed Excel Macros for all lipid 
classes according to the principles described previously (70).  
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3.2.4.3 Phosphorus assay 
In order to compare the phospholipid content determined by ESI-MS/MS a 
phosphorus assay was performed according to Bartlett and Lewis (74). Briefly 500µl 
of 70% perchloric acid was added to phosphate standards (0 - 100nmol) and 
samples and was incubated for 1h at 100°C. The samples were cooled to room 
temperature, before adding 1ml of 1% ammonium molybdate and 4% ascorbic acid 
and incubation for 2h at 37°C in a water bath. Finally the standard and samples were 
measured at 700nm in a microplate reader (Sunrise, Tecan, Crailsheim, Germany). 
 
3.2.5 Statistical analysis 
All data are expressed as mean ± S.D. and mean with range in parentheses, 
respectively. Statistical significance was determined by a student’s t-test for normally 
distributed data. Correlation analysis was performed using a bivariate correlation 
analysis with Pearson correlation coefficient. For significant results a linear 
regression analysis was performed to determine the correlation coefficient (R) and 
the coefficient of determination (R2). P-values <0.05 (*), <0.01 (**) and <0.001 (***) 
were considered statistically significant. Significance is depicted in the respective 
figures. All analyses were performed with a commercially available statistics 
computer program (SPSS 15.0 for Windows, SPSS GmbH Software, Munich, 
Germany). 
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4. Results 
4.1 Lipidomic analysis of circulating human blood cells 
The lipids of circulating blood cells are an important target to study in detail. The 
composition and organization of blood cell lipids and membranes is tightly controlled. 
Alteration leads to the loss of specific functions or early demise of cells in circulation 
(75). 
So far the analysis of blood cell lipid metabolism in human subjects has been largely 
confined to variations in metabolic and vascular diseases. Admittedly, most 
investigations have dealt with changes of defined lipids, cholesterol being probably 
the most intensively studied. For blood cells most of the lipid analyses in terms of 
lipid classes and mainly FA composition concentrated on red blood cells (RBC) (76-
81), however, there are also studies which were carried out for platelets (82-85) and 
peripheral blood mononuclear cells (PBMC) containing a mix of monocytes and 
lymphocytes (86). In most cases only one blood cell type was analyzed, rarely 
comparisons between FA pattern of blood cells were shown (77). Due to 
technological limitations, little attention was paid to a detailed examination of 
phospholipid species. The latest developments in ESI-MS/MS have opened new 
analytical possibilities to determine phospholipid species in different cell types by 
high sensitivity and high throughput methods (32-37;69;70). Recent publications 
showed already lipid patterns of blood cells using the new methodological 
approaches for RBC (87;88), PBMC (89), leukocytes (90) and granulocytes (91). 
However, there is so far no study of the different blood cells available which shows a 
detailed comparison of blood cell lipid species.  
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Therefore, a comprehensive analysis of most abundant lipid classes and their 
species was performed in circulating blood cells (monocytes, lymphocytes, 
granulocytes, platelets and RBC) of healthy donors to highlight specific features of 
the individual blood cells. The detailed lipid pattern of circulating blood cells may 
provide new insights into cellular lipid abnormalities in diseases such as 
atherosclerosis, obesity and type-2-diabetes and will help to understand how lipids 
affect pathologic states. 
 
4.1.1 Characteristics of cell donors and isolated blood cells 
Blood samples were obtained from nine healthy normo-lipidemic volunteers recruited 
from blood donors of our transfusion medicine laboratory with ApoE3/E3 phenotype. 
The clinical and laboratory phenotype of the blood donors are presented in Table 7. 
The blood donors were gender-balanced (5 male and 4 females) with a mean age of 
28 and normo-lipidemic with triglycerides and LDL below 150 mg/dl. The glucose 
values represent fasting level. After blood cell separation the purity levels of the blood 
cell fractions were determined and were shown to be higher than 95% for monocytes 
and platelets, higher than 85% for lymphocytes and granulocytes and above 98% for 
RBC. 
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Table 7: Characteristics of blood cell donors (n=9)1 
Parameters Value2 
Gender 5 males / 4 females 
Age (years) 28 (19-46) 
Total cholesterol (mg/dL) 182 (156-203) 
Triacylglycerols (mg/dL) 88 (53-138) 
HDL (mg/dL) 63 (42-75) 
LDL (mg/dL) 101 (85-145) 
Glucose (mg/dL) 88 (80-97) 
1 Nine healthy donors volunteered for the study. Displayed are their lab parameters which were 
analyzed by the ADVIA 1800 system (Siemens Healthcare Diagnostics GmbH, Bad Nauheim, 
Germany) 
2 All values are mean, range in parentheses 
 
4.1.2 Lipid class composition of blood cells 
In order to get an overview of the lipidome of circulating blood cells, cell 
homogenates corresponding to 100µg protein were subjected to lipid analysis by 
ESI-MS/MS analyzing the following lipid classes: PC, LPC, PE, PE-pl, PG, PI, SM, 
Cer, FC and CE. Moreover, the reproducibility of the presented data was shown by a 
second independent analysis. The coefficient of variation (CV) for the lipid classes 
was below 6% and for the lipid species in general below 10%. Only for a few species 
a CV up to 21% was observed. An additional gender dependent analysis did not 
reveal significant differences (data not shown).  
To evaluate the total lipid content (sum of the lipid classes analyzed) of the different 
blood cells a lipid to protein ratio as well as lipid content related to cell number was 
calculated. Total lipid content of the different blood cells varied between 41 to 179 
nmol/mg protein or 0.56 to 5.50 nmol/106 cells, respectively (Table 8). The highest 
mean content of total lipids was measured for platelets followed by RBC, monocytes, 
granulocytes, and the lowest in lymphocytes. The phospholipid content analyzed by 
ESI-MS/MS corresponded to the results measured by a phosphorus assay (Table 9).  
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The lipid class composition showed a low variation between different donors and 
characteristic pattern were observed for all cell types (Figure 7A). PC and 
unesterified cholesterol represented the predominant lipid fractions with a range of 
about 55 mol% for leukocytes and platelets and 63 mol% of RBC. The molar PC/FC 
ratio was 1.9 in monocytes, 1.3 in lymphocytes, 1.1 in granulocytes, 0.8 in platelets 
and 0.3 in RBC, respectively. The CE content in platelets of 2.5 mol% was at least 
four-fold higher than in the other analyzed blood cells. 
 
Table 8: Total lipid content of all circulating blood cells 
Illustrated are the total lipids of the different blood cells (monocytes, lymphocytes, granulocytes, 
platelets and red blood cells) which were normalized to same protein content (100µg) and analyzed by 
ESI-MS/MS. Total lipids represent all measured phospholipids (PC, SM, PE, PE-pl, PG, PI, PS, LPC, 
Cer, CE and FC) 
Blood cells Total lipid content (nmol/mg protein)1 
Total lipid content 
(nmol/106 cells)1 
Monocytes2 118.7 ± 16.7 5.50 ± 0.93 
Lymphocytes2 40.8 ± 10.2 3.28 ± 0.75 
Granulocytes2 84.1 ± 22.2 4.41 ± 0.89 
Platelets2 179.4 ± 38.9 0.48 ± 0.10 
Red blood cells3 154.2 ± 31.2 0.56 ± 0.11 
1 Values are mean±SD from nine different donors 
2 Total protein content of white blood cells and platelets was detected by a BCA assay 
3 Total protein content of red blood cells was related to the haemoglobin concentration 
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Table 9: Comparison between the lipid content of blood cell samples analyzed by ESI-MS/MS and by 
phosphorus assay 
Samples 
ESI-MS/MS 
(nmol/mg protein) 
Phosphorus-Assay 
(nmol/mg protein) 
monocyte 1 95,4 101,3 
monocyte 2 100,5 90,4 
monocyte 3 84,4 86,9 
monocyte 4 100,2 98,8 
monocyte 5 78,1 83,0 
lymphocyte 1 28,6 30,8 
lymphocyte 2 35,7 36,7 
lymphocyte 3 39,1 31,1 
granulocyte 1 50,3 54,0 
granulocyte 2 58,7 52,9 
granulocyte 3 66,8 66,1 
granulocyte 4 61,9 67,1 
granulocyte 5 76,1 64,5 
platelet 1 120,3 117,9 
platelet 2 145,0 150,4 
platelet 3 112,5 115,0 
platelet 4 154,1 146,1 
platelet 5 141,2 144,8 
platelet 6 109,4 104,8 
RBC 1 90,3 93,1 
RBC 2 102,3 99,9 
RBC 3 84,6 85,7 
RBC 4 114,5 112,7 
 
In order to assess the glycerophospholipid and sphingolipid content, the lipid pattern 
without FC and CE (Figure 7B) were used. Interestingly, granulocytes showed the 
highest PE-pl proportion with 21 mol% combined with a significantly lower PE fraction 
of 11 mol% compared to other leukocytes. The proportion of Cer in granulocytes was 
with 3.7 mol% 6-fold higher compared to other leukocytes and platelets (~3-fold 
compared to RBC). RBC differed substantially from other blood cells: A decreased 
PC and increased SM proportion resulted in a PC/SM ratio of 1.1, whereas the other 
cell types range from 2.4 to 3.5. Moreover, RBC were characterized by the lowest 
PE-pl and PI (< 1/3) as well as the highest PS proportion of all cell types analyzed. 
PG was for all cell types close to the limit of detection (therefore no evaluation of 
species profiles was shown below). A statistical analysis of the lipid classes for the 
analyzed blood cells is depicted in Table 10. 
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Figure 7: Lipid composition of monocytes, lymphocytes, granulocytes, platelets and red blood cells 
Leukocytes and platelets were separated by leukapheresis followed by counterflow centrifugation 
elutriation. Red blood cells were washed by repetitive centrifugation steps. The different lipid fractions 
were quantified by ESI-MS/MS. The displayed values are percent of the respective lipid class of all 
analyzed lipids (A) and glycerophospholipid/sphingolipids (B) for monocytes (black bars), lymphocytes 
(white bars), granulocytes (blue bars), platelets (green bars) and red blood cells (red bars), 
respectively. Apart from cholesteryl esters (CE) and free cholesterol (FC), the shown lipids are 
phosphatidylcholine (PC), sphingomyelin (SM), phosphatidylethanolamine (PE), PE-based 
plasmalogens (PE-pl), phosphatidylglycerol (PG), phosphatidylinositol (PI), phosphatidylserine (PS), 
lysophosphatidylcholine (LPC) and ceramide (Cer). Values are mean ± SD from nine different donors. 
Statistic calculations are shown in Table 10. 
Results 38
Table 10: Statistical significances of different lipid classes among the analyzed blood cells 
PC Monocytes Lymphocytes Granulocytes Platelets 
Monocytes     
Lymphocytes NS    
Granulocytes *** NS   
Platelets *** ** **  
RBC *** *** *** *** 
LPC Monocytes Lymphocytes Granulocytes Platelets 
Monocytes     
Lymphocytes **    
Granulocytes NS *   
Platelets *** NS ***  
RBC *** NS *** NS 
PE Monocytes Lymphocytes Granulocytes Platelets 
Monocytes     
Lymphocytes NS    
Granulocytes *** ***   
Platelets ** ** **  
RBC *** *** NS *** 
PE-pl Monocytes Lymphocytes Granulocytes Platelets 
Monocytes     
Lymphocytes **    
Granulocytes *** ***   
Platelets *** NS ***  
RBC *** *** *** *** 
PG Monocytes Lymphocytes Granulocytes Platelets 
Monocytes     
Lymphocytes NS    
Granulocytes *** **   
Platelets *** *** ***  
RBC *** *** ** ** 
PI Monocytes Lymphocytes Granulocytes Platelets 
Monocytes     
Lymphocytes **    
Granulocytes NS NS   
Platelets * NS NS  
RBC *** *** *** ** 
PS Monocytes Lymphocytes Granulocytes Platelets 
Monocytes     
Lymphocytes NS    
Granulocytes NS NS   
Platelets ** NS NS  
RBC NS NS NS NS 
SM Monocytes Lymphocytes Granulocytes Platelets 
Monocytes     
Lymphocytes **    
Granulocytes *** NS   
Platelets ** NS **  
RBC *** *** *** *** 
Cer Monocytes Lymphocytes Granulocytes Platelets 
Monocytes     
Lymphocytes NS    
Granulocytes *** ***   
Platelets * NS ***  
RBC *** *** *** *** 
FC Monocytes Lymphocytes Granulocytes Platelets 
Monocytes     
Lymphocytes *    
Granulocytes *** *   
Platelets *** ** NS  
RBC *** *** *** *** 
CE Monocytes Lymphocytes Granulocytes Platelets 
Monocytes     
Lymphocytes **    
Granulocytes NS **   
Platelets ** ** **  
RBC *** NS *** ** 
Abbreviations: NS =non-significant; * =p<0.05; ** = p<0.01; *** = p<0.001 
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4.1.3 Lipid species composition of blood cells 
Lipid profiles related to the total content of each respective lipid class were calculated 
for the evaluation of lipid species of the different blood cells (Figure 8-12). The 
performed mass spectrometric analysis only allows the determination of the total 
number of carbon atoms and double bonds in the FA moiety for lipid classes 
containing two FA esterified to the glycerol-backbone (PC, PE, PG, PI, PS). For 
example a PC 34:1 may represent different combinations of FA such as 18:0/16:1, 
16:0/18:1, etc. Moreover, the assignment to a bond type (acyl or ether) is based on 
the assumption that FA with odd-numbered carbon atoms constitute a negligible 
fraction. Lysophospholipids (LPC), sphingolipids (SM, Cer) and CE contain one FA 
denominated by the species nomenclature.  
The PC species pattern of the blood cells (Figure 8A and B) showed a broad 
distribution with PC 34:1 representing the major species beside PC 34:2 in RBC. A 
decreased level of highly polyunsaturated PC species (more than three double 
bounds) of 6.5 mol% was observed in granulocytes compared to monocytes (22 
mol%), lymphocytes (26 mol%), platelets (23 mol%) and erythrocytes (10 mol%). The 
amount of ether-phosphatidylcholine (PC O) species in granulocytes (about 40% of 
total PC) was clearly elevated compared to other circulating blood cells (12 to 24 %) 
(Figure 8B). For all PC O species granulocytes exhibited an increased proportion 
compared to other blood cell types, except highly polyunsaturated species where 
monocytes revealed the highest proportion. The LPC species profile (Figure 8C) 
displayed a dominance of saturated LPC species 16:0 and 18:0 in RBC and platelets, 
whereas leukocytes especially monocytes contained a high fraction of 
polyunsaturated LPC.  
Cellular PE species profiles (Figure 9A) showed a strikingly high percentage of PE 
38:4, most likely a combination of 18:0/20:4, in monocytes, lymphocytes and 
Results 40
platelets. Similarly, their predominant PE-pl species (Figure 9B) were arachidonic 
acid containing PE p16:0/20:4 and PE p18:0/20:4. Only granulocytes showed a 
higher content of monounsaturated species for PE as well as PE-pl species. 
Interestingly, granulocytes contained PE 36:1 and PS 36:1 (Figure 10B) as species 
with the highest abundance. 
Compared to other glycerophospholipid classes, for PI only a reduced number of 
species was detected (Figure 10A). PI 38:4 was the dominant lipid species for all 
analyzed cell types (>50 mol%), except for RBC where PI 36:2 composed nearly 50 
mol% at the expense of PI 38:4. PS species pattern (Figure 10B) showed two 
prominent species depending on the cell type: PS 36:1, particularly for granulocytes, 
and PS 38:4 for platelets and RBC. A chain length dependent analysis of 
glycerophosholipids (Table 11) demonstrated a striking shift for RBC compared to 
other cell types. Thus, for PC, PE, PI an increased fraction of species with shorter 
chain length was observed in RBC, whereas PS showed an elevated proportion of 
long chain species. SM species were assigned based on the assumption that di-
hydroxy C18:1 is the major sphingoid base in all blood cells (92). Also characteristic 
cellular SM species pattern (Figure 11A) with a dominant proportion of SM 16:0 
particularly in leukocytes were found. Compared to all analyzed cell types, platelets 
showed a unique SM species distribution, most prominent a more than 3-fold 
increased fraction of SM 20:0 and 22:0. Longer chain SM species (SM 24:1 and SM 
24:0) were significantly elevated for RBC in comparison to other blood cells (p<0.05). 
In principle the Cer species pattern (Figure 11B) was comparable to the SM pattern. 
One exception was a high percentage of Cer 16:0 in granulocytes of 65 mol%.  
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Figure 8: Phosphatidylcholine (PC), ether-phosphatidylcholine (PC O) and lysophosphatidylcholine 
(LPC) species composition of blood cells  
Cells were obtained and lipids extracted and analyzed as described in the legend to Figure 7. 
Displayed are mol% of PC (A) and PC-O (B) species related to total PC and LPC species (C) related 
to total LPC for monocytes (black bars), lymphocytes (white bars), granulocytes (blue bars), platelets 
(green bars) and red blood cells (red bars). Values are mean ± SD from nine different donors. 
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Figure 9: Phosphatidylethanolamine (PE) and PE-based plasmalogens (PE-pl) species composition of 
blood cells 
Blood cells were handled as described in the legend to Figure 7. Panel A shows PE species and panel 
B PE-pl species in mol% of the total lipid class. Monocytes are illustrated by black bars, lymphocytes 
by white bars, granulocytes by blue bars, platelets by green bars and red blood cells by red bars. 
Values are mean ± SD from nine different donors. 
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Figure 10: Phosphatidylinositol (PI) and phosphatidylserine (PS) species composition of blood cells 
Displayed are mol% of total PI (A) and PS (B) lipid species of monocytes (black bars), lymphocytes 
(white bars), granulocytes (dark grey bars), platelets (light grey bars) and red blood cells (red bars). 
Values are mean ± SD from nine different donors. 
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Figure 11: Sphingomyelin (SM) and ceramide (Cer) species composition of blood cells 
The sphingolipids of monocytes (black bars), lymphocytes (white bars), granulocytes (dark grey bars), 
platelets (light grey bars) and red blood cells (red bars) are displayed in mol% of total analyzed lipid 
class. SM species are shown in panel A. Cer species in panel B. Values are mean ± SD from nine 
different donors. 
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Table 11: Glycerophospholipids add up according to number of C-atoms 
PC 30 32 34 36 38 40  ≤ 34 >34  ≤ 36 >36 
Monocytes 0.7% 10.2% 18.9% 25.6% 1.4% 4.1%  29.8% 31.0%  55.4% 5.4% 
Lymphocytes 0.9% 11.0% 24.2% 28.7% 1.0% 3.1%  36.1% 32.8%  64.8% 4.1% 
Granulocytes 0.7% 6.4% 21.0% 22.5% 1.4% 1.7%  28.0% 25.6%  50.5% 3.1% 
Platelets 0.5% 6.3% 31.3% 30.0% 1.6% 4.0%  38.2% 35.6%  68.2% 5.6% 
Red blood cells 0.8% 5.6% 48.7% 24.9% 1.4% 1.5%  55.1% 27.8%  80.0% 2.9% 
             
PC-O 30 32 34 36 38 40  ≤ 34 >34  ≤ 36 >36 
Monocytes 0.2% 2.8% 4.8% 7.6% 6.4% 1.5%  7.8% 15.4%  15.4% 7.9% 
Lymphocytes 0.1% 1.6% 3.9% 3.5% 2.9% 0.5%  5.6% 6.9%  9.1% 3.4% 
Granulocytes 0.4% 6.6% 11.3% 12.7% 6.7% 1.6%  18.3% 21.0%  31.0% 8.3% 
Platelets 0.1% 0.7% 2.4% 4.4% 3.1% 0.7%  3.2% 8.2%  7.6% 3.8% 
Red blood cells 0.2% 0.9% 3.2% 4.2% 1.8% 0.4%  4.3% 6.4%  8.5% 2.2% 
             
PC + PC-O 30 32 34 36 38 40  ≤ 34 >34  ≤ 36 >36 
Monocytes 0.9% 13.0% 23.7% 33.2% 7.8% 5.5%  37.6% 46.5%  70.7% 13.3% 
Lymphocytes 1.0% 12.7% 28.1% 32.2% 3.9% 3.6%  41.8% 39.7%  73.9% 7.5% 
Granulocytes 1.1% 12.9% 32.3% 35.2% 8.1% 3.3%  46.3% 46.6%  81.5% 11.4% 
Platelets 0.6% 7.1% 33.7% 34.4% 4.8% 4.7%  41.4% 43.8%  75.7% 9.5% 
Red blood cells 1.0% 6.5% 51.9% 29.1% 3.2% 1.9%  59.4% 34.2%  88.6% 5.1% 
             
PE 30 32 34 36 38 40  ≤ 34 >34  ≤ 36 >36 
Monocytes / 0.2% 2.4% 21.6% 46.6% 24.3%  2.6% 92.5%  24.2% 70.9% 
Lymphocytes / 0.2% 3.4% 15.5% 58.2% 16.0%  3.6% 89.7%  19.2% 74.2% 
Granulocytes / 0.3% 4.7% 46.1% 31.0% 12.3%  5.0% 89.5%  51.1% 43.4% 
Platelets / 0.1% 2.9% 12.4% 65.6% 14.9%  3.0% 92.9%  15.4% 80.5% 
Red blood cells / 1.2% 22.2% 29.3% 34.1% 7.4%  23.5% 70.7%  52.8% 41.4% 
             
PE-pl 30 32 34 36 38 40  ≤ 34 >34  ≤ 36 >36 
Monocytes / 0.2% 3.7% 28.7% 50.3% 17.1%  3.9% 96.1%  32.6% 67.4% 
Lymphocytes / 0.5% 7.7% 28.3% 47.3% 16.2%  8.2% 91.8%  36.5% 63.5% 
Granulocytes / 0.3% 20.8% 40.2% 31.4% 7.2%  21.2% 78.8%  61.3% 38.7% 
Platelets / 0.1% 2.5% 26.3% 56.2% 14.9%  2.6% 97.4%  28.9% 71.1% 
Red blood cells / 0.3% 9.4% 23.5% 45.6% 21.2%  9.7% 90.3%  33.2% 66.8% 
             
PS 30 32 34 36 38 40     ≤ 36 >36 
Monocytes / 0.1% 1.7% 47.5% 18.5% 31.6%     49.2% 50.2% 
Lymphocytes / 0.2% 1.6% 33.4% 28.0% 35.6%     35.2% 63.7% 
Granulocytes / 0.1% 1.2% 75.3% 11.2% 11.7%     76.6% 22.9% 
Platelets / 0.0% 0.5% 32.7% 50.9% 14.8%     33.3% 65.8% 
Red blood cells / 0.2% 2.3% 11.9% 47.0% 37.8%     14.3% 84.8% 
             
PI 30 32 34 36 38 40     ≤ 36 >36 
Monocytes / / 1.2% 16.4% 75.1% 7.3%     17.6% 82.4% 
Lymphocytes / / 0.9% 19.0% 76.0% 4.0%     20.0% 80.0% 
Granulocytes / / 2.0% 24.1% 68.3% 5.6%     26.1% 73.9% 
Platelets / / 0.5% 11.1% 85.3% 3.1%     11.6% 88.4% 
Red blood cells / / 17.0% 60.7% 21.1% 1.1%     77.7% 22.3% 
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CE FA species were also characterized in detail (Figure 12). Interestingly, the CE 
18:2 (linoleic acid) fraction in platelets was with 55 mol% nearly 4-fold higher than in 
other circulating blood cells. An at least 2-fold higher content of CE 20:4 was 
measured in monocyte samples.  
In summary, lipid species analysis by ESI-MS/MS of the major circulating blood cell 
types from nine individuals demonstrated characteristic lipid class and lipid species 
patterns for each different cell type. 
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Figure 12: Cholesteryl ester (CE) species composition of blood cells 
CE species of monocytes (black bars), lymphocytes (white bars), granulocytes (dark grey bars), 
platelets (light grey bars) and red blood cells (red bars) are displayed in mol% of total analyzed CE. 
Values are mean ± SD from nine different donors. Only species above 5% related to total CE content 
of at least one blood cell type were shown. 
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4.2 Lipidomic analysis of platelet senescence 
Currently the factors controlling the lifespan of platelets both in vivo and in vitro are 
poorly understood. It is known that older platelets in vivo are less haemostatically 
active than younger ones and that senescent platelets have a decreasing ability to 
respond to physiological agonists and adhere to collagen (93). When platelet 
concentrates are stored ex vivo for purpose of transfusion a phenomenon called 
platelet storage lesion occurs which represents a non-physiological form of platelet 
death resulting in a loss of platelet function (94) and decrease of post-transfusion 
survival (95). Previously described changes can be classified into three broadly 
defined categories: metabolic alterations in the cytosol and mitochondria; platelet 
activation; and platelet senescence (96).  
Alterations during storage (97;98) already highlight the importance of cytoskeletal 
and lipid reorganization. The involvement of lipids in the development of the platelet 
storage lesion is also likely because of their hemostatic and structural importance 
and their chemical and physical lability (99). Hamid et al. (100) and Okuma et al. 
(101) found a loss of both cholesterol and phospholipids during platelet storage. The 
mechanisms behind the lipid loss are mainly microvesiculation and lipid peroxidation 
(99). Lipids also play a role in clearance of platelets from the circulation by the 
reticuloendothelial system of the spleen. Platelet aging in vivo is triggered by loss of 
membrane phospholipid asymmetry most important by phosphatidylserine (PS) 
exposure on the outer leaflet which is an important signal for ingestion by spleen 
macrophages (102). The loss of phospholipid asymmetry was also shown in an ex 
vivo study of stored platelets by Gaffet et al. (103). Furthermore mitochondria which 
are key organelles in the regulation of apoptosis decrease their membrane potential 
during platelet aging in vivo (104). In this context Leytin and Freedman (97) indicated 
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that the intrinsic (mitochondria-mediated) pathway may be involved in platelet 
apoptosis during platelet storage while the role of the extrinsic (death receptor-death 
ligand-dependent) pathway needs to be further elucidated. Beside “platelet 
apoptosis“ (“plateletptosis”) of this anucleate cells it seems that platelet activation is 
almost equally involved in the deterioration of platelets obtained by apheresis (105). 
The association between platelet lipid alterations and platelet activation was already 
demonstrated (106;107).  
Platelet lipid composition is also influenced by plasma lipoproteins whose interactions 
with platelets are crucial in atherosclerosis and thrombosis (108). LDL and HDL 
rapidly deliver SM, PC and PE to platelets (109) and also VLDL can transfer 
phospholipids to platelets (110). The phospholipid transfer from LDL to platelets is 
independent of high affinity binding of LDL to platelets (111). LDL sensitizes platelets 
via receptor-mediated signaling and lipid exchange (108). Related to these findings, 
LDL also directly contributes to the formation of platelet eicosanoids by supplying 
arachidonic acid either phospholipid bound or free (112).  
However, in context of platelet senescence the plasma and platelet lipid interactions 
were not studied so far. Therefore the changes of platelet lipids in platelet apheresis 
products were characterized and a correlation analysis between plasma and platelet 
lipids performed in this work. 
 
4.2.1 Characteristics of cell donors and collected platelet apheresis 
products 
The clinical and laboratory phenotype of the 50 healthy blood donors participating in 
the study are presented in Table 12. The blood donors, who routinely visited the 
department of transfusion medicine for platelet apheresis, were gender-balanced with 
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a mean age of 29. Platelet apheresis products of the study fulfilled all criteria for 
transfusion acceptance.  
 
Table 12: Characteristics of platelet donors (n=50)1 
Parameters Value2 
Gender 28 males / 22 females 
Age (years) 29 (19-51) 
Total cholesterol (mg/dL) 173 (114-241) 
Triacylglycerols (mg/dL) 95 (37-161) 
HDL (mg/dL) 64 (33-100) 
LDL (mg/dL) 83 (55-114) 
VLDL (mg/dL) 26 (8-39) 
Platelets (/nL) 228 (177-319) 
1 Fifty healthy donors volunteered for the study. Displayed are their lab parameters which were 
analyzed by the ADVIA 1800 system (Siemens Healthcare Diagnostics GmbH, Bad Nauheim, 
Germany).  
2 All values are mean, range in parentheses. 
 
4.2.2 Validation of platelet gel-filtration separation 
Recent publications propose Sepharose chromatography for in vitro and in vivo 
assays to study platelet function (113;114) because platelet isolation by density 
gradient centrifugation leads already to significant platelet activation. Pre-tests were 
carried out to establish optimal platelet isolation conditions by gel-filtration. The 
collected fractions were analyzed for cell number, protein and lipid content (Figure 
13A). A high platelet count could only be detected in fractions 3-5 where also an 
elevation of the protein and lipid content was observed. To determine the purity of the 
collected fractions different platelet and plasma specific proteins were analyzed by 
blotting from the different fractions (Figure 13B). The thrombospondin receptor CD36 
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was detected in fractions 3-6. The plasma proteins transferrin and apolipoprotein A-I, 
A-IV and C-I raised after fraction 5. Only ApoE seemed to be also present in the 
platelet fraction. In order to exclude contamination of lipoproteins, only fractions 3-5 
were used for further platelet analysis. Platelet activation was tested by flow 
cytometry giving evidence of nearly any activation during gel-filtration isolation (data 
not shown).  
 
4.2.3 Total lipid content of senescent platelets 
To monitor changes in the lipidome of platelet apheresis products during five days of 
storage lipid analysis was performed by ESI-MS/MS covering the following lipid 
classes: PC, LPC, PE, PE-pl, PG, PI, SM, Cer, FC and CE. The time limit was 
chosen because regulations restricted the use of platelet concentrates older than five 
days in transfusion medicine. 
During storage time of five days the total lipid content of platelets decreased by 
10.3% from 5,306 to 4,759 nmol/1010 platelets (p<0.05, paired t-test) (Figure 14) due 
to an 8.9% loss of phospholipids and an 18.1% loss of cholesterol. Vice versa the 
total lipid content of plasma increased by 5.2% from 5,323 to 5,600 nmol/ml plasma 
(p<0.001, paired t-test).  
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Figure 13: Validation of gel-filtration isolation. 
Panel A shows the counted platelet cell number per fraction of the gel-filtration separation procedure 
which was measured by ADVIA 120 system (Siemens Healthcare Diagnostics GmbH, Bad Nauheim, 
Germany). It also displays the protein content (in µg/10nl) of each fraction measured by a BCA assay 
as well as the total lipid content (in nmol/ml) per fraction analyzed by ESI-MS/MS. All three displayed 
units are adapted to a similar exponent on the y-axis. Values are mean±SD from 10 different donors. 
Panel B displays the total lipid content of the different fractions during gel-filtration isolation measured 
by ESI-MS/MS as described in materials and methods. Panel B shows a SDS-PAGE of different 
platelet (CD36, transferrin) and lipoprotein specific proteins (ApoA-I, ApoA-IV, ApoC-I, ApoE) per gel-
filtration isolated fraction. 
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Figure 14: Total lipid content of senescent platelet concentrates.  
Platelets were isolated by gel-filtration procedure and plasma by centrifugation. The different lipid 
fractions were quantified by ESI-MS/MS. Displayed is the total lipid content of platelets (in nmol/1010 
platelets) (blue bars) and plasma (in nmol/ml plasma) (yellow bars) during an aging period of five days 
after apheresis. Significant changes between day 0 and day 5 are calculated by a donor specific, 
paired t-test. Values are mean ± SD from 50 different donors.  
 
4.2.4 Lipid class composition of senescent platelets 
The lipid class composition showed a low variation between different donors except 
for CE and characteristic pattern were observed for platelets (Figure 15A) and 
plasma (Figure 15B). PC and FC represented the predominant lipid fractions with 
nearly 50 mol% for platelets considering all measured lipid classes. During five days 
of platelet storage significant increases of 69% for Cer, 32% for LPC, 8% for SM and 
49% for CE were found as well as a decrease of 10% for FC fractions related to day 
0. The platelet PC fraction did not change significantly. In plasma significant changes 
during storage were detected in LPC (increase of 43%), PC (decrease of 20%) and 
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FC (decrease of 24%) fractions related to day 0. The dominating plasma lipid class 
was CE which increased from 52 to 59 mol% from day 0 to day 5.  
To better understand the significant increase of Cer during platelet aging the whole 
sphingolipid pattern was further analyzed by MS (Figure 16A-C). Beside the major 
sphingolipids SM and Cer (Figure 15A) DihCer and LacCer were found above 3 
mol% of all analyzed sphingolipids (Figure 16A). LacCer showed as expected a ten 
times higher ratio (Figure 16C) and percentage of displayed sphingolipids (Figure 
16A) compared to GlcCer in platelets. During storage a significant increase of GlcCer 
from 0.17 to 0.27 mol% was detected while the LacCer content did not change 
significantly (Fig. 16A). Due to the significant increase of Cer and GlcCer during 
storage of platelet concentrates significant changes of the Cer/LacCer and 
GlcCer/LacCer ratios were obtained between day 0 and day 5 (Figure 16C). For all 
other sphingolipids except SM (Figure 15A) and DihSM highly significant decreases 
of 63% for SPH, 78% for SPA, 68% for SPC, 55% for S1P and 89% for SA1P related 
to collection day were observed (Figure 16A). Thus, highly significant changes of 
ratios for SPH, SPA, SPC, S1P and SA1P in relation to rising Cer were obtained 
during the storage time of five days (Figure 16B).  
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Figure 15: Lipid composition of senescent platelet concentrates.  
Platelets and plasma were prepared as described in the legend to Figure 14. The displayed values are 
percent of the respective lipid class of all analyzed lipids in platelets (A) and appropriate plasma 
samples (B) during the platelet age of 5 days in different colours: day 0 (dark blue bars), day 1 (orange 
bars), day 2 (green bars), day 3 (yellow bars), day 4 (blue bars), day 5 (pink bars). Apart from 
cholesteryl esters (CE) and free cholesterol (FC), the shown lipids are phosphatidylcholine (PC), 
sphingomyelin (SM), phosphatidylethanolamine (PE), PE-based plasmalogens (PE-pl), 
phosphatidylglycerol (PG), phosphatidylinositol (PI), phosphatidylserine (PS), lysophosphatidylcholine 
(LPC) and ceramide (Cer). Values are mean ± SD from 50 different donors.  
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Figure 16: Sphingolipid composition and ratios of senescent platelets 
Platelets were handled as described in the legend to Figure 14. Displayed are mol% of the respective 
sphingolipid classes of all analyzed sphingolipids in platelets stored for 5 days (A). Panel B displays 
the ratios of Cer to SPH, SPA, SPC, S1P and SA1P. Panel C illustrates the ratios of Cer to GlcCer 
and LacCer and of GlcCer to LacCer. For calculation of lipid ratios the quantitative values of respective 
sphingolipids in nmol/108 platelets were used. The lipid values for each day of storage are shown in 
different increments (day 0 (dark blue bars), day 1 (orange bars), day 2 (green bars), day 3 (yellow 
bars), day 4 (blue bars), day 5 (pink bars)). Values are mean ± SD from 50 different donors. 
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4.2.5 Lipid species composition of senescent platelets 
Lipid species profiles related to the total content of the respective lipid class were 
determined for all collected platelet concentrates (Figure 17 and 18). The performed 
mass spectrometric analysis only allows the determination of the total number of 
carbon atoms and double bonds in the FA moiety for lipid classes containing two FA 
esterified to the glycerol-backbone. For example a PS 36:1 may represent different 
combinations of FA such as 18:0/18:1, 16:0/20:1, etc. Moreover, the assignment to a 
bond type (acyl or ether) is based on the assumption that FA with odd-numbered 
carbon-atoms constitute a negligible fraction. LPC, Cer and CE contain one FA 
denominated by the species nomenclature. Lipid species pattern which are 
significantly changed during platelet aging were PS (Figure 17A), LPC (Figure 17B) 
and Cer (Figure 17C). The composition of remaining lipid species which are not 
significantly altered during platelet storage was already shown in the first part of this 
thesis (4.1.3) (115). The major PS species were PS 36:1 and PS 38:4 with more than 
60 mol% of total PS. During storage a shift from shorter, less unsaturated to longer, 
more unsaturated PS species was observed. Regarding LPC an elevation of 7.1 
mol% occurred for saturated LPC 18:0. Cer species showed a clear increase of Cer 
18:0 from 3 to 7 mol% as well as Cer 20:0 from 9 to 14 mol% while the longer Cer 
chains (Cer 23:0, Cer 24:1 and Cer 24:0) declined in total about 10 mol%. For 
plasma samples of platelet concentrates significant PS (Figure 18A) and LPC (Figure 
18B) lipid species shifts were detected during storage. The three major plasma PS 
species showed a species specific relative increase for PS 36:1 of 19% and PS 38:4 
of 90% and a decrease of PS 40:7 of more than 50% between collection and storage 
of five days (Figure 18A). In case of LPC the saturated species LPC 16:0 and LPC 
18:0 increased both about 27% and 51% among the species, respectively. In 
contrast, the disaturated LPC 18:2 decreased from 28 to 16 mol% (Figure 18B). 
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Figure 17: Lipid species profiles of senescent platelets. 
Platelets were treated as described in the legend to Figure 14. Displayed are mol% of 
phosphatidylserine (PS) (A), lysophosphatidylcholine (LPC) (B) and ceramide (Cer) (C) species 
related to total lipid content of the appropriate lipid class for senescent platelets stored for 5 days. The 
lipid values for each day of storage are shown in different increments (day 0 (dark blue bars), day 1 
(orange bars), day 2 (green bars), day 3 (yellow bars), day 4 (blue bars), day 5 (pink bars). Values are 
mean ± SD from 50 different donors. 
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Figure 18: Lipid species profiles of plasma used for platelet concentrate storage. 
Plasma was obtained and lipids extracted as described in the legend to Figure 14. Panel A shows 
phosphatidylserine (PS) species and panel B lysophosphatidylcholine (LPC) species in mol% of total 
lipid class. The different bars illustrate the age of plasma between plasma collection (day 0) and end of 
platelet concentrate storage (day 5). Values are mean ± SD from 50 different donors. 
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Regarding the CE lipid species pattern of platelets and plasma an identical 
distribution was observed together with a similar trend during storage of platelet 
concentrates with no significant changes (Figure 19). 
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Figure 19: Cholesteryl ester (CE) species composition of plasma and platelets of apheresis products.  
CE species of day 0 (dark blue bars), day 1 (orange bars), day 2 (green bars), day 3 (yellow bars), day 
4 (blue bars) and day 5 (pink bars) altered plasma (A) and platelets (B) are displayed in mol% of total 
analyzed CE. Values are mean ± SD from 50 different donors.  
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4.2.6 Correlation analysis of lipid changes during storage  
In order to evaluate changes in the lipid profiles during storage of platelet apheresis 
products correlation analysis was performed. Normalization of the data was achieved 
by calculation of ratios day 1 to 0 and day 5 to 0 of lipid fractions, respectively. Since 
the changes observed for the plasma samples may be related to lecithin-cholesterol-
acyltransferase (LCAT) activity, PC and LPC (Figure 20A) as well as FC and CE 
changes (Figure 20B) were correlated with each other. In both cases the changes 
revealed significant correlation with negative regression supporting the hypothesis of 
an ongoing esterification reaction of FC to CE. 
As a next step it was asked how changes in the plasma influenced platelet lipid 
composition. Therefore, correlation of lipid changes in plasma and platelets was 
analyzed. Except for PC (Figure 21A) significant correlations with positive regression 
for LPC (Figure 21B), FC (Figure 21C) and CE (Figure 21D) were detected indicating 
a direct link between certain plasma and platelet lipids. Taken together these data 
indicate that LCAT activity changes lipid composition in the plasma of platelet 
concentrates which consequently affects platelet LPC, FC and CE composition. 
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Figure 20: Correlation analysis between plasma lipids of apheresis products.  
Displayed are the bivariate correlation analyses with Pearson correlation coefficient between the ratios 
day1/day0 (black circles) and day5/day0 (white circles) of different plasma lipids. The lipid ratios after 
one and five days of storage compared to collection day were calculated from 50 different donors. 
Panel A shows the correlation between plasma phosphatidylcholine (PC) and lysophosphatidylcholine 
(LPC) ratios and panel B the correlation between plasma free cholesterol (FC) and cholesteryl esters 
(CE). A linear regression analysis was performed to determine the correlation coefficient (R) and the 
coefficient of determination (R2). 
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Figure 21: Correlation analysis between platelet and plasma lipids of apheresis products.  
Bivariate correlation analyses with Pearson correlation coefficient combined with a linear regression 
analysis was performed between platelet and plasma lipids. The ratios of one (black circles) and five 
(white circles) day aged platelet apheresis products in relation to collection day (day 0) were analyzed 
for the following lipids in plasma and platelets: phosphatidylcholine (PC) (A), lysophosphatidylcholine 
(LPC) (B), free cholesterol (FC) (C) and cholesteryl esters (CE) (D). The values are obtained from 50 
different donors. 
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5. Discussion 
5.1 Lipidomic analysis of circulating human blood cells 
The blood cell compartment can be regarded as a liquid organ. To identify novel 
cellular biomarkers, blood cells are easily accessible as compared to tissues and 
solid organs. The composition of lipid species of different human blood cells appears 
to be unique and cell specific and any deviation may disrupt cellular homeostasis 
(116).  
In general the data showed a good correlation to previous studies presenting mostly 
lipid class analysis in these cells. Phospholipid classes of platelets (82) as well as 
their detailed phospholipid species composition (83) correspond to the obtained 
results. PC, PE, PE-pl, PS and SM phospholipid species of PBMC determined by a 
normal-phase LC–MS/MS method (89) also correlated to the results for the major 
phospholipid species of monocytes and lymphocytes. A study by Postle et al. (90) 
investigated the dynamics of the PC metabolism and observed a similar species 
pattern of lymphocytes and neutrophils as in the present study. Moreover, the 
distribution of lipid classes including PC/SM and PC/FC ratios of RBC fitted well to 
measured data (76;79).  
The most interesting differences of the lipid species profile were found for 
granulocytes, platelets and RBC. More than 100 billion granulocytes are produced 
everyday and enter the blood (46). Neutrophils, the main granulocyte cell type, 
display about 50-70% of leukocytes. They have a short life time of only 8-20 hours. If 
they are not activated and constitutively undergo apoptosis (117). Hence, an 
elevated Cer content of granulocytes (predominantly Cer 16:0, Figure 11B), which 
was at least three-fold higher compared to other analyzed blood cells (Figure 7B), 
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could be a sign of pro-apoptosis of neutrophils. In addition, granulocytes are 
characterized by a decreased level of highly polyunsaturated FA species (≥ three 
double bounds) in the main phospholipid classes and an elevated PE-pl lipid content. 
It is well known that neutrophils produce superoxide to kill pathogens like bacteria. 
Because plasmalogens are described as cellular antioxidants (118), both a low 
content of polyunsaturated FA, as a major target of free radical attack (119), and a 
high content of plasmalogens may be protective mechanisms of granulocytes against 
oxidative stress. Additionally, a high PE-pl content may reflect a high peroxisomal 
activity, since essential steps of the plasmalogen biosynthesis reside in peroxisomes 
(11;120). 
Another interesting observation was the high CE content of platelets (Figure 7A) with 
CE 18:2 as main species (Figure 12). CE 18:2 also represents the main CE species 
in plasma (35) while the cellular FC esterifying enzyme sterol O-acyltransferase 
(SOAT1) preferentially uses oleoyl-CoA (18:1) (121). Therefore the question arises 
whether the high CE content of platelets originates from plasma lipoproteins. To 
answer this question an additional study is required analyzing in more detail the 
effect of plasma lipids on platelet lipids (see 4.2). 
The membrane fluidity of blood cells is mainly determined by their 
phospholipid/cholesterol molar ratio (79) and seems to be adapted to the cellular 
function. The PC/FC ratio of platelets was 0.8 and clearly lower in comparison to 
leukocytes (1.9 in monocytes, 1.3 in lymphocytes and 1.1 in granulocytes) (Figure 
7A). The increased amount of FC relative to phospholipids in platelets reflects more 
rigid and non-fusogenic membrane features which may be necessary to prevent 
premature clot formation. In contrast, the highest PC/FC ratio in monocytes may 
relate to their migratory capability into the endothelial space and phagocytic activity, 
which require a fluidic membrane. RBC have to be able to repeatedly pass through 
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capillaries four times smaller than their own size (122) and to keep their biconcave 
shape to provide a large surface for gas exchange (123). This may be reflected by a 
low PC/SM ratio together with the highest cholesterol content in RBC (Figure 7A) 
indicating a less fluid membrane (79).  
In summary, different circulating blood cells of healthy human donors are 
characterized by unique lipid class and species pattern. The lipid composition of 
blood cells matched with their functional requirements concerning blood cell shape 
and size in the vascular system. The current study provides for the first time a 
detailed overview of lipid species in circulating blood cells generated using ESI-
MS/MS as a single platform. Moreover, this study may be a reference for the search 
of novel lipid biomarker in circulating blood cells in patients with blood cell-related 
disorders, vascular and metabolic diseases, thrombosis and systemic inflammation. 
 
5.2 Lipidomic analysis of platelet senesence 
The present study identified significant changes in lipid profiles of platelets and 
plasma during storage of platelet concentrates. In agreement with previous studies a 
loss of total lipids in platelets was found (100;101) that is accompanied by an 
increase of plasma lipids (Figure 14) providing evidence for lipid cession due to 
microparticle shedding during platelet senescence.  
The data showed a good correlation to previous studies concerning the lipid class 
distribution of platelets (82;115) and the total lipid content (115). This total lipid loss 
with a decline of 9% for total phospholipids and 18% for free cholesterol matched well 
with the results detected by Hamid et al. where a loss of 15% total cholesterol and a 
loss of up to 11% for phospholipids was observed for platelets stored at 20°C (100). 
Okuma et al. found a loss of 30% for cholesterol and 15% for phospholipids during 
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storage at 4°C (101). The higher difference compared to the latter study was 
probably due to isolation and storage of platelets at 4°C. Another explanation may be 
related to the preparation of platelets since previous studies use washing and several 
centrifugation steps. In contrast to theses studies the platelets in this study were 
separated by gel-filtration which was already recommended for analysis of platelet 
function (113;114). Additionally, it was shown that this approach provided negligible 
platelet activation and a clear separation of lipoprotein and platelet fractions to 
exclude lipid contamination in the platelet analysis (Figure 13).  
The question arises whether lipid alterations observed in this study are associated 
with storage lesion and apoptosis? In non-nucleated red blood cells a process called 
“eryptosis” occurs due to energy or antioxidant depletion causing a loss of membrane 
PS asymmetry, with consequent exposure of PS at the red blood cell surface (124). 
Similarly, senescent, activated platelets also loose membrane asymmetry (125).  
Leytin et al. (105) observed an increase of 13.3% PS exposure after five days 
storage of platelet apheresis products which may be related to PS species shifts both 
in platelets and plasma (Figure 17A and 18A). Another potential explanation may 
also be connected to the release of PS-rich microvesicles which are able to re-
associate with the platelet membrane (126). Besides changes of PS species, one 
novel finding of this study was a relative increase of 69% of the Cer fraction (Figure 
15A) as well as a shift in the Cer species profile (Figure 17C) during platelet storage. 
Although platelets are anucleate cells and do not show cell growth, reticulated 
platelets seem to undergo terminal differentiation (127) and programmed cell death 
during senescence (128;129), biological processes in which sphingolipids play an 
important role (130). Previous studies already mentioned the function of certain Cer 
species in apoptosis. In this context Cer 16:0 (131;132) and Cer 18:0 (133) were 
highlighted. It was also described that Cer generation and oxidative stress are 
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connected to cellular death (134). However, no significant amounts of oxidized lipid 
species were observed in the mass spectrometry data. It is tempting to speculate that 
observed lipid changes for PS and Cer are probably signs of rising apoptosis playing 
a minor role during conventional storage with more impact after platelet storage 
prolongation.  
Further sphingolipid metabolites were analyzed by LC-MS/MS because the 
sphingolipid metabolism in platelets has special features (Figure 22). Platelets are 
deficient in de novo sphingolipid biosynthesis starting from condensation of L-serine 
and palmitoyl-CoA by serine palmitoyl CoA transferase (SPTLC) (135). Platelets also 
lack S1P lyase (SGPL) activity (136). Yang et al. (137) found out that exogenously 
added [3H]SPH and [3H]C6-Cer were rapidly converted to [3H]S1P while the 
conversion to [3H]SM was very weak (138) indicating a persistently active spingosine 
kinase (SPHK) activity (130). However, the maximum time points for [3H]SPH and 
[3H]C6-Cer stimulation in this study ranged between 15 and 180 min, respectively 
(137). In contrast the platelet senescence in this thesis was studied until day five of 
storage revealing an increase of Cer with an associated decrease of SPH, SPA, 
SA1P, S1P and SPC (Figure 16A/B). It seems that the high SPH kinase activity 
decreases during aging, moving towards a more Cer dominated the equilibrium 
(Figure 22). That means, distinct from the well-known SM breakdown via acid 
sphingomyelinase (SMPD) to Cer, that the presence of a transmembrane cycling 
pathway in platelets starts with S1P phosphatase (SGPP) (130). The conversion of 
SPH to Cer occurs via intracellular Cer synthase (LASS) (139). The different LASS 
homologs synthesize Cer with a different FA composition (140). In this study Cer 
16:0, Cer 18:0 and Cer 20:0 significantly increased during aging (Figure 17C) 
indicating a main activity of LASS1, 4 and 5 (140). However, no isoform specificity for 
sphingolipid enzymes in platelets has been described so far. To fully understand the 
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sphingolipid metabolism during aging, it will be necessary to measure the distinct 
enzyme activities and trace the pathways of certain sphingolipid metabolites after 
longer incubation of labeled SPH and SPA. 
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Figure 22: Sphingolipid metabolism in platelets during senescence 
The first step of de novo sphingolipid synthesis in platelets, the condensation of L-serine and 
palmitoyl-CoA, is blocked in platelets (135). Platelets are also the only cell type known where no S1P 
lyase activity was detected (141). Platelets use SPH at the outer leaflet of the plasma membrane and 
in the extracellular space (135;142). Cer stands in the center of the whole sphingolipid metabolism. 
During aging SM, Cer and GlcCer were increased (marked in red) while SPH, SPA, S1P, SA1P and 
SPC were decreased (marked in green) (adapted from (143;144)). 
 
Another interesting observation of the present study is the trend of plasma lipid 
changes in platelet concentrates during storage. Decreases of PC and FC were 
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accompanied with increases of LPC and CE (Figure 15B). These changes can be 
explained by FC to CE conversion due to action of LCAT. In order to substantiate the 
hypothesis, a correlation analysis of the lipid composition changes observed in 
plasma was performed and significant correlations for PC and LPC and notable for 
FC and CE were found, respectively (Figure 20 A and B).  
Since this study analyzed plasma and platelets of 50 platelet concentrates, it was 
possible to study the influence of lipid changes in plasma on the platelet lipid 
composition by correlation analysis. This way evidence was provided that increases 
of LPC and CE as well as the decline of FC fractions in platelets were caused by 
changes in the plasma compartment during storage (Figure 21B-D). An explanation 
why any correlation between the changes of plasma and platelet PC fractions (Figure 
21A) was observed may be that platelets metabolize and do not simply “store” PC. 
The exceptional high content of CE in platelets compared to other blood cells was 
already shown in Figure 7A (115). Further evidence for a CE plasma uptake came 
from the similarity of plasma and platelets CE species profiles (Figure 19). This is 
also substantiated by a specific substrate preference of the different esterifying 
enzymes. Intracellular sterol O-acyltransferase (SOAT1) preferentially uses oleoyl-
CoA (18:1) for storage in lipid droplets while CE 18:2, the main CE species in 
platelets (Figure 19), is a specific product of the LCAT reaction in plasma (121). 
Taken together these data clearly argue for the uptake of lipoprotein lipid 
components into platelets during storage. These changes due to LCAT activity may 
be of relevance for transfusion of platelet concentrates since LPC, generated during 
storage, was shown to activate NADPH oxidase, potentially playing a role in severe 
complications of transfusion therapy (145;146). 
The question arises how plasma lipoproteins are “stored” within the platelets? There 
are three major mechanisms explaining the lipid transfer from the plasma 
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compartment to the platelets: (i) internalization of lipoprotein particles into the cells 
(e.g. by endocytosis or trapping in the open canalicular system (OCS)), (ii) total 
(specific and unspecific) binding of lipoproteins to the platelet surface and (iii) 
selective uptake of phospholipids by cellular membranes. Concerning the first 
mechanism (i) most reports agree that endocytosis of lipoprotein particles into 
platelets is unlikely (147). However, the uptake and trapping of plasma components 
within the OCS seem to be rather possible. Platelets enhance their cell surface by an 
OCS with tubular invaginations (148) constituting up to 25% of total platelet volume 
(149). Measurements of OCS diameter of platelet electron microscopic pictures 
revealed a range between 70-160 nm in resting platelets, therefore large enough to 
incorporate even a VLDL particle (30-80 nm) (Figure 23). During platelet storage the 
total volume fraction of the OCS increased from 7% at day 1 to 17% at days 5 and 8 
(149). Concerning the two other described mechanisms (ii) and (iii) Engelmann et al. 
(109) pointed out that both yielded comparable proportions of lipoprotein particles 
bound to the platelets. This group also mentioned that the incorporation of 
lipoprotein-derived phospholipids into platelet membranes may become more and 
more independent of lipoprotein binding to the cells after prolonged incubation of 
lipoproteins with platelets. This may be particularly relevant under in vitro conditions 
during storage of platelet concentrates for several days. In this context the 
incorporation of plasma components into platelet membranes would play a minor role 
compared to trapping in a dilated OCS. However, the hypothesis of engulfment of 
protein and lipid plasma components in the OCS has to be further elucidated by 
labeling experiments. 
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Figure 23: The open canalicular system (OCS) of the platelets 
Panel A illustrates the ultrastructure of resting human platelets (equatorial plane) taken by electron 
microscopy. Panel B shows a schematic drawing of the three-dimensional reconstruction of the OCS 
in a human platelet which is distributed throughout the cytoplasm and consists of one continuous 
tubular system inside the cell, although it has many braches and protrusions (150). The arrowheads 
indicate the orificium of the OCS. 
 
In summary, the current study provides for the first time a detailed overview of lipid 
species shifts in senescent platelets and plasma analyzed by ESI-MS/MS. Moreover, 
clear evidence for LCAT-mediated changes in plasma and platelet lipid compositions 
were shown. However, further investigations have to show how much these lipid 
changes contribute to poor post-transfusion survival and haemostatic function of 
platelets. The current study could contribute to enhance our understanding of cellular 
senescence and platelet storage. 
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6. Conclusion 
The blood cells and plasma harbours a massive amount of information about the 
functioning of all tissues and organs in the body (40). Therefore an accurate, fast, 
and affordable analysis of the cellular components of blood is of prime interest for 
laboratory and transfusion medicine and clinical research. The field of lipidomics 
adds an additional layer of information to data derived from proteomics and genomics 
providing additional knowledge of blood cell function. Therefore the aim of this thesis 
was to compare the individual blood cell lipid pattern of healthy donors and to 
highlight specific differences of the individual blood cells in relation to function.  
In the first part of the study the different blood cells, monocytes, lymphocytes, 
granulocytes, platelets and red blood cells (RBC), of healthy human individuals were 
analyzed using electrospray ionization tandem mass spectrometry (ESI-MS/MS). 
Striking differences among the examined blood cells were detected. It was shown 
that the different blood cells were characterized by unique lipid class and species 
patterns. The predominant lipid classes were phosphatidylcholine (PC) and free 
cholesterol (FC) with cell type specific PC/FC ratios as markers of membrane fluidity 
which were 1.9 in monocytes, 1.3 in lymphocytes, 1.1 in granulocytes, 0.8 in platelets 
and 0.3 in RBC, respectively. Beside a 3-fold elevated ceramide (Cer) level of 2.6 
mol%, granulocytes revealed the highest percentage of phosphatidylethanolamine-
based plasmalogens and a decreased fraction of highly polyunsaturated (≥ 3 double 
bonds) species compared to other cell types. RBC also showed a remarkable shift of 
glycerophospholipid chain length. In platelets a nearly 4-fold increase of the 
cholesterol ester (CE) 18:2 (linoleic acid) fraction (55 mol% of total CE) together with 
the highest content of total CE in all analyzed blood cells was found. Furthermore a 
nearly identical distribution of CE lipid species pattern between platelets and plasma 
was observed.  
For this reason platelets were chosen as the blood cell type to be analyzed in more 
detail in related, therapeutic blood products. In this second part of the work plasma 
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and platelet lipids of 50 platelet apheresis concentrates stored under agitation for five 
days at 22°C were studied. This limit was chosen because legal regulations restrict 
the use of platelet concentrates older than five days in transfusion medicine. During 
storage time the lipid content decreased by 10% in platelets and increased by 5% in 
plasma. A more detailed analysis of additional sphingolipids revealed significant 
decreases of 63% for sphingosine, 78% for sphinganine, 68% for 
sphingosylphosphorylcholine, 55% for sphingosine-1-phosphate and 89% for 
sphinganine-1-phosphate and an increase of 69% for Cer between lipid fractions of 
fresh and five days aged platelets providing novel information about the sphingolipid 
metabolism in platelets in relation to senescence. In case of glycerophospholipids 
and sterols the following changes in lipid fractions relative to day of preparation were 
found: Increases of 32% lysophosphatidylcholine (LPC) and 49% CE and a decrease 
of 10% FC in platelets; elevation of 43% LPC and 14% CE and a decline of 20% PC 
and 24% FC in plasma. Significant lipid species shifts were also observed for 
phosphatidylserine, Cer and LPC. Really interesting results concerning lipid transfer 
between the plasma and the cell compartment arose from calculations of lipid 
correlations. The data provided clear evidence for lecithin-cholesterol acyltransferase 
(LCAT) mediated esterification of FC and generation of CE and LPC in the plasma of 
platelet concentrates. These lipid changes also correlated between plasma and 
platelets for LPC, FC and CE fractions. It could be concluded that plasma lipid 
changes impact the platelet lipids, in particular CE species, leading to the 
characteristic platelet lipid distribution observed in the first part of this work. 
The whole study perfectly demonstrates that the application of ESI-MS/MS for 
lipidomic analysis leads to novel, interesting results useful for a better understanding 
of the blood cell compartment. The obtained results could serve as a reference for 
further studies with blood cell material of patient cohorts, opening new opportunities 
in drug and biomarker development for blood cells, in particular at the various stages 
in the preclinical and early clinical categories.  
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